WO2022200469A1 - A dominant negative protein of rad51 for treating cancer - Google Patents
A dominant negative protein of rad51 for treating cancer Download PDFInfo
- Publication number
- WO2022200469A1 WO2022200469A1 PCT/EP2022/057695 EP2022057695W WO2022200469A1 WO 2022200469 A1 WO2022200469 A1 WO 2022200469A1 EP 2022057695 W EP2022057695 W EP 2022057695W WO 2022200469 A1 WO2022200469 A1 WO 2022200469A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rad51
- smrad51
- protein
- dominant negative
- cancer
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 172
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 159
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- 201000011510 cancer Diseases 0.000 title claims abstract description 33
- 101100355586 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rhp51 gene Proteins 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 108010068097 Rad51 Recombinase Proteins 0.000 claims abstract 21
- 230000014509 gene expression Effects 0.000 claims description 105
- 239000003795 chemical substances by application Substances 0.000 claims description 69
- 239000012634 fragment Substances 0.000 claims description 53
- 108020001507 fusion proteins Proteins 0.000 claims description 31
- 102000037865 fusion proteins Human genes 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 101001046894 Homo sapiens Protein HID1 Proteins 0.000 claims description 19
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 101000949825 Homo sapiens Meiotic recombination protein DMC1/LIM15 homolog Proteins 0.000 claims description 11
- 102100022877 Protein HID1 Human genes 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 108090000143 Mouse Proteins Proteins 0.000 claims description 7
- 238000002619 cancer immunotherapy Methods 0.000 claims description 7
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 7
- 102000001195 RAD51 Human genes 0.000 claims 20
- 206010006187 Breast cancer Diseases 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 13
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 9
- 230000036952 cancer formation Effects 0.000 abstract description 9
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 9
- 230000005751 tumor progression Effects 0.000 abstract description 8
- 206010061309 Neoplasm progression Diseases 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 5
- 102000002490 Rad51 Recombinase Human genes 0.000 abstract 2
- 235000018102 proteins Nutrition 0.000 description 111
- 210000004027 cell Anatomy 0.000 description 83
- 241000699670 Mus sp. Species 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 53
- 229920001223 polyethylene glycol Polymers 0.000 description 43
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 238000002744 homologous recombination Methods 0.000 description 20
- 230000006801 homologous recombination Effects 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- -1 pentaerythriol Chemical compound 0.000 description 17
- 239000002202 Polyethylene glycol Substances 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 108700019146 Transgenes Proteins 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000002779 inactivation Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 230000006698 induction Effects 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000012423 maintenance Methods 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 8
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 102000045327 human DMC1 Human genes 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 101000620735 Homo sapiens DNA repair protein RAD51 homolog 1 Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 101100355584 Mus musculus Rad51 gene Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 102000051623 human RAD51 Human genes 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010063493 Premature ageing Diseases 0.000 description 6
- 208000032038 Premature aging Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000031448 Genomic Instability Diseases 0.000 description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000025084 cell cycle arrest Effects 0.000 description 5
- 208000037966 cold tumor Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000012361 double-strand break repair Effects 0.000 description 4
- 208000037967 hot tumor Diseases 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000024312 invasive carcinoma Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000003938 response to stress Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000008718 systemic inflammatory response Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000000453 cell autonomous effect Effects 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- 238000009643 clonogenic assay Methods 0.000 description 3
- 231100000096 clonogenic assay Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000003612 morphinomimetic agent Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- KQTSOJHOCCWAEH-UHFFFAOYSA-N n'-(2,5-dioxopyrrolidin-1-yl)butanediamide Chemical compound NC(=O)CCC(=O)NN1C(=O)CCC1=O KQTSOJHOCCWAEH-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ULTTYPMRMMDONC-UHFFFAOYSA-N 5-[(2,5-dihydroxyphenyl)methyl-[(2-hydroxyphenyl)methyl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(N(CC=2C(=CC=CC=2)O)CC=2C(=CC=C(O)C=2)O)=C1 ULTTYPMRMMDONC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 102000013519 Lipocalin-2 Human genes 0.000 description 2
- 108010051335 Lipocalin-2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001415846 Procellariidae Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000009454 functional inhibition Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000006618 mitotic catastrophe Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002914 neoplasic effect Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 2
- 229940121367 non-opioid analgesics Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960005343 ondansetron Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000007112 pro inflammatory response Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- COTYIKUDNNMSDT-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 COTYIKUDNNMSDT-UHFFFAOYSA-N 0.000 description 1
- BTBWSRPRAGXJJV-UHFFFAOYSA-N 2h-benzotriazole;carbonic acid Chemical compound OC(O)=O.C1=CC=C2NN=NC2=C1 BTBWSRPRAGXJJV-UHFFFAOYSA-N 0.000 description 1
- QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- GIYAQDDTCWHPPL-UHFFFAOYSA-N 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
- BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 108091008717 AR-A Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100257121 Arabidopsis thaliana RAD5A gene Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 1
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 244000089742 Citrus aurantifolia Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100300839 Mus musculus Rai14 gene Proteins 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 101710186414 N-succinylglutamate 5-semialdehyde dehydrogenase Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100411639 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-41 gene Proteins 0.000 description 1
- 101100351735 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ptr-4 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 101150070307 PFA4 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101150081777 RAD5 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 101100411620 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rad15 gene Proteins 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 1
- UVAZQQHAVMNMHE-BBRMVZONSA-N [(3s,4s)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1[C@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-BBRMVZONSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229960003687 alizapride Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229960004564 benzquinamide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229950000011 betaprodine Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001034 bromopride Drugs 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 229960001791 clebopride Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical group ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
- 229960000569 ethoheptazine Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229950010373 methallatal Drugs 0.000 description 1
- XMQICEWOKPEQRG-UHFFFAOYSA-N methallatal Chemical compound CC(=C)CC1(CC)C(=O)NC(=S)NC1=O XMQICEWOKPEQRG-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960000767 metopimazine Drugs 0.000 description 1
- BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
- NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 description 1
- 229950006080 metopon Drugs 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000002113 nanodiamond Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OSJJYEUEJRVVOD-UHFFFAOYSA-N pipamazine Chemical compound C1CC(C(=O)N)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 OSJJYEUEJRVVOD-UHFFFAOYSA-N 0.000 description 1
- 229950008580 pipamazine Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052624 sepiolite Inorganic materials 0.000 description 1
- 235000019355 sepiolite Nutrition 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
- 229960003397 thioproperazine Drugs 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
- RAD51 a 339-amino acid protein, plays a major role in homologous recombination (HR) of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks.
- HR homologous recombination
- ssDNA single stranded DNA
- RAD51 promotes the search for homology, strand invasion and strand exchange stages of the process.
- HR is essential for genome stability maintenance, inactivation of HR factors is directly associated with cancer susceptibility.
- RAD5 1 mutations are paradoxically not commonly found in human cancer.
- the inventors reported that the expression of the engineered RAD51 dominant negative protein SMRAD5 1 suppresses HR and affects the DNA replication dynamics, leading to replication stress and genome instability in unchallenged primary cells as well as in transformed cells.
- the inventors characterize the molecular mechanism of HR inhibition (Inhibition of the RAD51/ssDNA activity of homology search and strand exchange) and they show that this is not associated with the stimulation of alternative mutagenic repair pathways.
- SMRad51 in vivo in young growing mice leads to an abrupt lethality partially caused by a systemic inflammatory response.
- SMRad51 expression leads to premature aging but not to tumorigenesis.
- HR partners of RAD51 such as BRCA1 or BRCA2
- BRCA1 or BRCA2 leads to cancer susceptibility.
- both in adult and young growing mice proliferative tissues are preferentially affected, particularly progenitor cells that are replicating. This is consistent with the impact of RAD51 suppression on DNA replication dynamic. These tissues accumulate markers of DNA damages and apoptosis.
- the tissues expresses inflammatory cytokines and immune cells (macrophages, lymphocyte B) are recruited suggesting that the innate immunity system was activated.
- loss of function of the tumor suppressor TRP53 which should suppress apoptosis and reduce senescence, in fact does not increase tumorigenesis but, on the opposite, it reduced the life span of SMRad51 expressing adult mice.
- the inventors have shown that the expression of SMRAD51 in TRP53 devoid cells increase mitotic catastrophe. Therefore, the absence of cell cycle checkpoint resulting from TRP53 ablation precipitates SMRAD51- expressing cells, which exhibit replication stress, toward mitotic catastrophe and death.
- the inventors decided to directly address this hypothesis and investigated the effects of RAD51 functional disruption by dominants negative like the protein SMRAD51 on tumorigenesis and tumor progression using a mouse model of breast cancer.
- the present invention relates to dominants negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
- the invention is defined by its claims.
- the mouse model PyMT is a model of breast tumors predisposition.
- SMRAD51 functional inactivation increases the activation of DNA damage and replication stress response in pre-neoplasic and neoplastic lesions in vivo.
- data show that functional inactivation of RAD51 causes cell cycle arrest in G2, cell death and inhibit cell proliferation.
- a first aspect of the invention relates to a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
- the term “dominant negative of RAD51” denotes a molecule/protein/product which adversely affects endogenous RAD51 (the normal protein) and thus which can still interact with the same elements as RAD51 and/or with RAD51 partners and/or endogenous RAD51 itself, but block its function that’s is to say its role in homologous recombination (HR) of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks.
- HR homologous recombination
- a dominant negative of RAD51 can be the protein SMRAD51, a fragment of SMRAD51 or any agent for SMRAD51 protein expression, the protein RAD51 K133A, a fragment of RAD51 K133A or any agent for RAD51 K133A protein expression, the protein RAD51 K133R, a fragment of RAD51 K133R or any agent for RAD51 K133R protein expression, the protein RAD51 T131P, a fragment of RAD51 T131P or any agent for RAD51 T131P protein expression, the protein RAD51 IDA, a fragment of RAD51 IDA or any agent for RAD51 IDA protein expression, the protein DMC1, a fragment or variant of DMC1 or any agent for DMC1 protein expression.
- the dominant negative is a RAD51 which is not the human RAD51 that is to say a RAD51 from another specie than human.
- the dominant negative is an human, mouse or yeast chimeric protein (SMRAD51) or a mutant human, a mutant mouse or chimeric protein RAD51 K133A, RAD51 K133R, RAD51 T31P, RAD51 IDA or DMC1.
- SMRAD51 mouse or yeast chimeric protein
- the invention also relates to the SMRAD51 protein or fragment thereof or an agent for SMRAD51 protein expression for use in the treatment of a cancer in a subject in need thereof.
- an agent for SMRAD51 protein expression denotes an agent which can instore the SMRAD51 protein expression.
- an agent for SMRAD5 1 protein expression can be a nucleic acid encoding for SMRAD51 or for a fragment of SMRAD51.
- an agent for the dominant negative proteins of the invention expression denotes an agent which can instore the dominant negative proteins expression.
- an agent for the dominant negative proteins expression can be a nucleic acid encoding for the dominant negative proteins of the invention or for a fragment thereof.
- the invention relates to a dominant negative protein or fragment thereof and/or an agent for the dominant negative protein expression for use in the treatment of a cancer in a subject in need thereof.
- the dominant negative protein is selected from the group consisting of an human, mouse or yeast chimeric protein (SMRAD51) or a mutant human, a mutant mouse or chimeric protein RAD51 K133A, RAD51 K133R, RAD51 T31P, RAD51 IDA or DMC1
- a subject denotes a mammal.
- a subject according to the invention refers to any subject (particularly an human) afflicted with or susceptible to be afflicted with a cancer.
- the cancer may be selected in the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, esophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer
- treatment refers to both prophylactic or preventive treatment as well as curative or disease-modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
- the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
- therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
- a therapeutic regimen may include an induction regimen and a maintenance regimen.
- the phrase “induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
- the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
- An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
- maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
- a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
- SMRAD51 has its general meaning in the art and refers to the RAD51 dominant negative protein.
- RAD51 is a 339-amino acid protein that plays a major role in homologous recombination of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks. In this process, an ATP dependent DNA strand exchange takes place in which a single-strand invades base-paired strands of homologous DNA molecules. When loaded on the ssDNA, RAD51 promotes the search for homology and strand pairing stages of the process.
- the protein SMRAD51 has an of amino acid sequence SEQ ID NO: 1.
- the SMRAD51, RAD51 K133A, RAD51 K133R, RAD51 IDA or DMC1 proteins of the invention are isolated, synthetic or recombinant proteins.
- the SMRAD51 protein comprises a sequence as set forth by SEQ ID NO: 1.
- the SMRAD51 protein comprises a sequence as set forth by SEQ ID NO: 2.
- the RAD51 K133A human protein comprises a sequence as set forth by SEQ ID NO: 3.
- Amino acids sequence of the human RAD51 K133A (SEQ ID NO: 3) (see J. M. Stark et al, 2002):
- the RAD51 K133 A mouse protein comprises a sequence as set forth by SEQ ID NO: 4.
- the RAD51 K133R human protein comprises a sequence as set forth by SEQ ID NO: 5.
- Amino acids sequence of the human RAD51 K133R (SEQ ID NO: 5) (see J. M. Stark et al, 2002):
- the RAD51 K133R mouse protein comprises a sequence as set forth by SEQ ID NO: 6.
- the RAD51 T13 IP human protein comprises a sequence as set forth by SEQ ID NO: 7.
- Amino acids sequence of the human RAD51 T131P (SEQ ID NO: 7) (see: A. T. Wang et al., 2015):
- the RAD51 T13 IP mouse protein comprises a sequence as set forth by SEQ ID NO: 8.
- Amino acids sequence of the mouse RAD51 T131P (SEQ ID NO: 8) (see: A. T. Wang et al., 2015):
- the RAD51 IDA human protein comprises a sequence as set forth by SEQ ID NO: 9.
- Amino acids sequence of the human RAD51 IDA (SEQ ID NO: 9, reference number PMID: 31562309):
- the RAD51 IDA mouse protein comprises a sequence as set forth by SEQ ID NO: 10.
- the human DMC1 variant 1 protein comprises a sequence as set forth by SEQ ID NO: 11.
- the human DMC1 variant 2 protein comprises a sequence as set forth by SEQ ID NO: 12.
- a dominant negative protein can be a protein with the amino acid sequence of RAD 51 (SEQ ID NO: 13 or 14) with at least 10 amino acids added at the N- Terminal part or C-terminal part of RAD51.
- Amino acids sequence of the mouse RAD51 (SEQ ID NO: 14): MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRT GKT QICHTL AVTCQLPIDRGGGEGK AMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTD Y S GRGEL S ARQMHL ARFLRMLLRL ADEF G V A V VITN Q V V AQ VDGAAMF AAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
- the dominant negative proteins of the present invention comprises or consists of an amino acid sequence having at least 70% of identity with SEQ ID NO: 1, 2, 3, 4, 5, 6 7, 8, 9, 10, 11, 12, 13 or 14.
- a first amino acid sequence having at least 70% of identity with a second amino acid sequence means that the first sequence has 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; or 99, or 100% of identity with the second amino acid sequence.
- Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, 1990).
- the Ar SMRAD51 pin protein of the invention is a functional conservative variant of the SMRAD51 protein according to the invention.
- the term “function-conservative variant” are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the dominant negative proteins of the invention, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like).
- a “function-conservative variant” also includes an dominant negative proteins of the invention which has at least 70 % amino acid identity and which has the same or substantially similar properties or functions as the native or parent dominant negative proteins of the invention to which it is compared.
- Functional properties of the dominant negative proteins of the invention of the invention could typically be assessed in any functional assay as described in the EXAMPLE.
- the fragment of the dominant negative proteins of the invention can be a peptide of at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 consecutive amino acids from SEQ ID NO: 1, 2, 3, 4, 5, 6 7, 8, 9, 10, 11, 12, 13 or 14.
- SMRad51 expression leads to a systemic proinflammatory response in both adult and growing mice and activate innate immunity.
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to turn cold tumors into hot tumors.
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to turn tumors who do not respond to immunotherapy into tumors who do not respond to immunotherapy.
- the SMRAD51 or fragment thereof and/or an agent for the SMRAD51 expression is able to turn cold tumors into hot tumors.
- cold tumor has its general meaning in the art and refers to immune-excluded tumors and immune-desert tumors, i.e a tumor that is not likely to trigger a strong immune response. Cold tumors usually do not respond to immunotherapy. Most cancers of the breast, ovary, prostate, pancreas, and brain (glioblastoma) are considered cold tumors.
- hot tumor has its general meaning in the art and refers to immune-inflamed tumors characterized by high T-cell infiltration, increased interferon-g (IFN- g) signaling, expression of PD-L1. Hot tumors usually respond to immunotherapy.
- IFN- g interferon-g
- SMRDA51 inhibits homologous recombination (HR). They have demonstrated that SMRDA51 binds damaged DNA and represses GC (gene conversion) but does not stimulate non conservative mechanisms (SSA and A-EJ), as detailed in So A. et al. Nucleic Acids Res. 2022 Feb 8. Thus, SMRDA51 prevents genomic instability and thus mutagenesis, which is a is a hallmark of aging and cancer.
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to prevent excessive genomic instability and/or mutagenesis.
- the SMRAD51 or fragment thereof and/or an agent for the SMRAD51 expression is able to prevent excessive genomic instability and/or mutagenesis.
- a further aspect of the present invention relates to a fusion protein comprising the protein or peptide according to the invention (a dominant negative of RAD51 according to the invention) that is fused to at least one heterologous polypeptide.
- fusion protein refers to the protein or peptide according to the invention that is fused directly or via a spacer to at least one heterologous polypeptide.
- the fusion protein comprises the protein or peptide according to the invention that is fused either directly or via a spacer at its C-terminal end to the N-terminal end of the heterologous polypeptide, or at its N-terminal end to the C-terminal end of the heterologous polypeptide.
- the term “directly” means that the (first or last) amino acid at the terminal end (N or C-terminal end) of the protein or peptide is fused to the (first or last) amino acid at the terminal end (N or C-terminal end) of the heterologous polypeptide.
- the last amino acid of the C-terminal end of said protein or peptide is directly linked by a covalent bond to the first amino acid of the N-terminal end of said heterologous polypeptide, or the first amino acid of the N-terminal end of said protein or peptide is directly linked by a covalent bond to the last amino acid of the C-terminal end of said heterologous polypeptide.
- the term “spacer” refers to a sequence of at least one amino acid that links the protein or peptide of the invention to the heterologous polypeptide. Such a spacer may be useful to prevent steric hindrances.
- the heterologous polypeptide is a cell-penetrating peptide, a Transactivator of Transcription (TAT) cell penetrating sequence, a cell permeable peptide or a membranous penetrating sequence.
- TAT Transactivator of Transcription
- cell-penetrating peptides are well known in the art and refers to cell permeable sequence or membranous penetrating sequence such as penetratin, TAT mitochondrial penetrating sequence and compounds (Bechara and Sagan, 2013; Jones and Sayers, 2012; Khafagy el and Morishita, 2012; Malhi and Murthy, 2012).
- the proteins, peptides or fusion proteins of the invention may be produced by any technique known per se in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or in combination. Knowing the amino acid sequence of the desired sequence, one skilled in the art can readily produce said proteins, peptides or fusion proteins, by standard techniques for production of amino acid sequences. For instance, they can be synthesized using well-known solid phase method, preferably using a commercially available peptide synthesis apparatus (such as that made by Applied Biosystems, Foster City, California) and following the manufacturer’s instructions. Alternatively, the proteins, peptides or fusion proteins of the invention can be synthesized by recombinant DNA techniques as is now well-known in the art.
- these fragments can be obtained as DNA expression products after incorporation of DNA sequences encoding the desired (poly) peptide into expression vectors and introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the desired (poly) peptide, from which they can be later isolated using well- known techniques.
- proteins, peptides or fusion proteins of the invention can be used in an isolated (e.g., purified) form or contained in a vector, such as a membrane or lipid vesicle (e.g. a liposome).
- a vector such as a membrane or lipid vesicle (e.g. a liposome).
- proteins, peptides or fusion proteins according to the invention may be modified in order to improve their therapeutic efficacy and their stability using well-known techniques.
- modification of therapeutic compounds may be used to decrease toxicity, increase circulatory time, or modify biodistribution.
- the toxicity of potentially important therapeutic compounds can be decreased significantly by combination with a variety of drug carrier vehicles that modify biodistribution.
- a strategy for improving drug stability is the utilization of water-soluble polymers.
- Various water-soluble polymers have been shown to modify biodistribution, improve the mode of cellular uptake, change the permeability through physiological barriers; and modify the rate of clearance from the body.
- water- soluble polymers have been synthesized that contain drug moieties as terminal groups, as part of the backbone, or as pendent groups on the polymer chain.
- Pegylation is a well-established and validated approach for the modification of a range of polypeptides (Chapman, 2002).
- the benefits include among others: (a) markedly improved circulating half-lives in vivo due to either evasion of renal clearance as a result of the polymer increasing the apparent size of the molecule to above the glomerular filtration limit, and/or through evasion of cellular clearance mechanisms; (b) reduced antigenicity and immunogenicity of the molecule to which PEG is attached; (c) improved pharmacokinetics; (d) enhanced proteolytic resistance of the conjugated protein (Cunningham- Rundles et.ak, 1992); and (e) improved thermal and mechanical stability of the PEGylated polypeptide.
- the proteins, peptides or fusion proteins of the invention may be covalently linked with one or more polyethylene glycol (PEG) group(s).
- PEG polyethylene glycol
- One skilled in the art can select a suitable molecular mass for PEG, based on how the pegylated polypeptide will be used therapeutically by considering different factors including desired dosage, circulation time, resistance to proteolysis, immunogenicity, etc.
- the PEG of the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CEP ("methoxy PEG").
- a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called branched PEGs.
- Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol.
- a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide.
- One form of PEGs includes two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini et ak, 1995).
- the hydroxyl end groups of the polymer molecule must be provided in activated form, i. e. with reactive functional groups (examples of which include primary amino groups, hydrazide (HZ), thiol, succinate (SUC), succinimidyl succinate (SS), succinimidyl succinamide (SSA), succinimidyl proprionate (SPA), succinimidyl carboxymethylate (SCM),benzotriazole carbonate (BTC), N- hydroxysuccinimide (NHS), aldehyde, nitrophenyl carbonate (NPC), and tresylate (TRES)).
- Suitable activated polymer molecules are commercially available, e. g.
- the polymer molecules can be activated by conventional methods known in the art, e. g. as disclosed in WO 90/13540.
- activated linear or branched polymer molecules for use in the present invention are described in the Shearwater Polymers, Inc. 1997 and 2000 Catalogs (Functionalized Biocompatible Polymers for Research and pharmaceuticals, Polyethylene Glycol and Derivatives, incorporated herein by reference).
- activated PEG polymers include the following linear PEGs : NHS-PEG (e g.
- SPA-PEG SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM- PEG
- NOR-PEG BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs such as PEG2-NHS.
- the conjugation of the proteins, peptides or fusion proteins and the activated polymer molecules is conducted by use of any conventional method. Conventional methods are known to the skilled artisan. The skilled person will be aware that the activation method and/or conjugation chemistry to be used depends on the attachment group(s) of the polypeptides as well as the functional groups of the PEG molecule (e.g., being amine, hydroxyl, carboxyl, aldehyde, ketone, sulfhydryl, succinimidyl, maleimide, vinylsulfone or haloacetate).
- the attachment group(s) of the polypeptides as well as the functional groups of the PEG molecule (e.g., being amine, hydroxyl, carboxyl, aldehyde, ketone, sulfhydryl, succinimidyl, maleimide, vinylsulfone or haloacetate).
- the proteins, peptides or fusion proteins of the invention are conjugated with PEGs at amino acid D and E (for COOH), T, Y and S (for OH), K (for MB), C (for SH if at least one cysteine is conserved) or/and Q and N (for the amide function).
- additional sites for PEGylation can be introduced by site-directed mutagenesis by introducing one or more lysine residues. For instance, one or more arginine residues may be mutated to a lysine residue.
- additional PEGylation sites are chemically introduced by modifying amino acids on proteins, peptides or fusion proteins of the invention.
- PEGs are conjugated to the polypeptides or fusion proteins through a linker.
- Suitable linkers are well known to the skilled person.
- a preferred example is cyanuric chloride ((Abuchowski et ah, 1977); US 4,179, 337).
- the pegylated polypeptides provided by the invention have a serum half-life in vivo at least 50%, 75%, 100%, 150% or 200% greater than that of an unmodified polypeptide.
- the agent for SMRAD51 protein expression of the invention is selected from the group consisting of an isolated, synthetic or recombinant nucleic acid encoding for a dominant negative of RAD51 according to the invention and particularly SMRAD5 1 protein, a nucleic acid sequence encoding for the fusion protein, a nucleic acid encoding a fragment of a dominant negative of RAD51 according to the invention and particularly SMRAD51 protein, a nucleic acid encoding a fragment of a peptide according to the invention, a cell expressing a dominant negative of RAD51 according to the invention and particularly SMRAD51 protein, and agent inducing a dominant negative of RAD51 expression according to the invention and particularly SMRAD51 gene expression and their combinations.
- said nucleic acid encoding for SMRAD51 proteins comprises a sequence as set forth by SEQ ID NO: 15 or 16.
- Nucleic acid sequence of the chimeric yeast/mouse SMRAD51 (SEQ ID NO: 15): tgtctcaagttcaagaacaacatatatcagagtcacagcttcagtacgggaacggttcgttgatgtccactgtaccagcagac ctttcacagtcagtcgttgatggaaacggcaacggtagcagcgaagatattgaggccaccaacggcgctatgcaaatgcagcttgaag caagtgcagatacttcagtggaagaagaaagttttggtccacagcctatttcacggttagagcagtgtggcataaatgccaatgatgtgtga agaaattagagccggttaccatacagtggaggctgtgcttatgcaccgaagaaggaacta
- Nucleic acid sequence of the chimeric yeast/human SMRAD51 (SEQ ID NO: 16): atgtctcaagttcaagaacaacatatatcagagtcacagcttcagtacgggaacggttcgttgatgtccactgtaccagcaga cctttcacagtcagtcgttgatggaaacggcaacggtagcagcgaagatattgaggccaccaacggcgcaatgcagatgcagcttga agcaaatgcagatacttcagtggaagaagaaagctttggcccacaacccatttcacggttagagcagtgtggcataaatgccaacgatg tgaagaaattggaagaagctggattccatactgtggaggtggtggtccaaaggattccaaaatatta
- said nucleic acid encoding for the human DMC1 variant 1 protein comprises a sequence as set forth by SEQ ID NO: 17.
- Nucleic acid sequence of the human DMC1 variant 1 (SEQ ID NO: 17): atgaaggaggatcaagttgtggcggaagaaccaggattccaagatgaagaggaatctttgtttcaagatattgacctgttaca gaaacatggaattaacgtggctgacattaagaaactgaaatcagtaggaatctgtaccatcaaaggtatacagatgacaacaagaaga gctctatgcaatgtcaaaggactctcagaagccaaagtagacaagattaaagaggcagcgaacaaactaattgaaccaggattcttgac tgcatttgagtatagtgaaaagaggaaaatggttttccatatcaccaccgggagccaggaattttgataagttactaggaggtggaattgaaag
- said nucleic acid encoding for the human DMC1 variant 2 protein comprises a sequence as set forth by SEQ ID NO: 18.
- Nucleic acid sequence of the human DMC1 variant 2 (SEQ ID NO: 18): atgaaggaggatcaagttgtggcggaagaaccaggattccaagatgaagaggaatctttgtttcaagatattgacctgttaca gaaacatggaattaacgtggctgacattaagaaactgaaatcagtaggaatctgtaccatcaaaggtatacagatgacaacaagaaga gctctatgcaatgtcaaaggactctcagaagccaaagtagacaagattaaagaggcagcgaacaaactaattgaaccaggattcttgac tgcatttgagtatagtgaaaagaggaaaatggttttccatatcaccaccgggagccaggaattttgataagttactaggaggtggaattgaaag
- Nucleic acid sequence of the human RAD51 (SEQ ID NO: 19): atggcaatgcagatgcagcttgaagcaaatgcagatacttcagtggaagaagaaagctttggcccacaacccatttcacggt tagagcagtgtggcataaatgccaacgatgtgaagaaattggaagaagctggattccatactgtggaggctgttgcctatgcgccaaagaggagctaataatattaagggaattagtgaagccaaagctgataaaattctggctgaggcagctaaattagttccaatgggtttcacca ctgcaactgaattccaccaaaggcggtcagagatcatacagattactactggctccaaagagcttgacaaactacttggtggaattgagagactacttcaa
- Nucleic acid sequence of the mouse RAD51 (SEQ ID NO: 20): atggctatgcaaatgcagcttgaagcaagtgcagatacttcagtggaagaagaaagttttggtccacagcctatttcacggtta gagcagtgtggcataaatgccaatgatgtgaagaaattagaagaagccggttaccatacagtggaggctgttgcttatgcaccgaaga aggaactaataaatattaagggaattagtgaagccaaagctgacaaaattctgactgaggcagcaaaattggttccaatgggtttcacca cggcaactgagtttcaccagcggttcccagcggttcagagatcatacagataactactggctccaaagagctggacaagctgcttcaa
- the nucleic acid encoding for the dominant negative protein of the invention for example comprises or consists of a sequence at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 % identical to sequence SEQ ID NO: 15, 16, 17, 18, 19 or 20.
- a sequence "encoding" an expression product such as a DNA, RNA, polypeptide, protein, or enzyme
- a sequence "encoding" an expression product is a nucleotide sequence that, when expressed, results in the production of that DNA, RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme.
- a coding sequence for a protein may include a start codon (usually ATG) and a stop codon.
- nucleic acid sequences can be obtained by conventional methods well known to those skilled in the art.
- said nucleic acid is a DNA or RNA molecule, which may be included in a suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage, viral vector, a liposome, or a nanoparticle like the clay mineral sepiolite or nano-diamonds.
- a further object of the present invention relates to a vector and an expression cassette in which a nucleic acid molecule encoding for a proteins, peptides or fusion proteins of the invention is associated with suitable elements for controlling transcription (in particular promoter, enhancer and, optionally, terminator) and, optionally translation, and also the recombinant vectors into which a nucleic acid molecule in accordance with the invention is inserted.
- recombinant vectors may, for example, be cloning vectors, or expression vectors.
- vector means the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g. transcription and translation) of the introduced sequence.
- a DNA or RNA sequence e.g. a foreign gene
- Any expression vector for animal cell can be used.
- suitable vectors include pAGE107 (Miyaji et ah, 1990), pAGE103 (Mizukami and Itoh, 1987), pHSG274 (Brady et ah, 1984), pKCR (O'Hare et ah, 1981), pSGl beta d2-4 (Miyaji et ah, 1990) and the like.
- Plasmids include replicating plasmids comprising an origin of replication, or integrative plasmids, such as for instance pUC, pcDNA, pBR, and the like.
- viral vectors include adenoviral, lentiviral, retroviral, herpes virus and AAV vectors.
- recombinant viruses may be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses.
- virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc.
- Detailed protocols for producing such replication-defective recombinant viruses may be found for instance in WO 95/14785, WO 96/22378, US 5,882,877, US 6,013,516, US 4,861,719, US 5,278,056 and WO 94/19478.
- promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40 (Mizukami and Itoh, 1987), LTR promoter and enhancer of Moloney mouse leukemia virus (Kuwana et al., 1987), promoter (Mason et al., 1985) and enhancer (Gillies et al., 1983) of immunoglobulin H chain and the like.
- a further aspect of the invention relates to a host cell comprising a nucleic acid molecule encoding for a protein, peptide or a fusion protein according to the invention or a vector according to the invention.
- a subject of the present invention is a prokaryotic or eukaryotic host cell genetically transfected or transformed with at least one nucleic acid molecule or vector according to the invention.
- transformation for prokaryotic host cell
- transfection for eukaryotic host cell
- a prokaryotic host cell that receives and expresses introduced DNA or RNA has been "transformed”.
- a eukaryotic host cell that receives and expresses introduced DNA or RNA has been "transfected”.
- prokaryotic cells for expressing and producing proteins, peptides or fusion proteins of the invention, prokaryotic cells, in particular E. coli cells, will be chosen.
- it is not mandatory to produce the proteins, peptides or fusion proteins of the invention in a eukaryotic context that will favour post-translational modifications (e.g. glycosylation).
- prokaryotic cells have the advantages to produce protein in large amounts. If a eukaryotic context is needed, yeasts (e.g. saccharomyces strains) may be particularly suitable since they allow production of large amounts of proteins.
- typical eukaryotic cell lines such as CHO, BHK-21, COS-7, C127, PER.C6, YB2/0, HEK293, mononuclear macrophage/monocyte-lineage hematopoietic precursors, Haematopoietic stem cells, Mononuclear precursor cells, osteoblast or inactive osteoclast could be used, for their ability to process to the right post-translational modifications of the fusion protein of the invention.
- insect cells can be used for expressing and producing proteins, peptides or fusion proteins of the invention.
- the construction of expression vectors in accordance with the invention, and the transformation of the host cells can be carried out using conventional molecular biology techniques.
- the protein, peptide or the fusion protein of the invention can, for example, be obtained by culturing genetically transformed cells in accordance with the invention and recovering the proteins, peptides or fusion proteins expressed by said cell, from the culture. They may then, if necessary, be purified by conventional procedures, known in themselves to those skilled in the art, for example by fractional precipitation, in particular ammonium sulfate precipitation, electrophoresis, gel filtration, affinity chromatography, etc. In particular, conventional methods for preparing and purifying recombinant proteins may be used for producing the proteins in accordance with the invention.
- a further aspect of the invention relates to a method for producing a protein, peptide or a fusion protein of the invention comprising the step consisting of: (i) culturing a transformed host cell according to the invention under conditions suitable to allow expression of said protein, peptide or fusion protein; and (ii) recovering the expressed protein, peptide or fusion protein.
- the agent for SMRAD51 protein expression of the invention is an agent inducing SMRAD51 gene and peptide expression selected from the group consisting of, but not limited to, Human Cytomegalovirus (HCMV), VHL/E HCMV strain, and TB40/E HCMV strain.
- HCMV Human Cytomegalovirus
- VHL/E HCMV strain VHL/E HCMV strain
- TB40/E HCMV strain TB40/E HCMV strain.
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is administered in combination with one or more anti-cancer.
- the present invention relates to a dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention in combination with one or more anti-cancer agent for use in the treatment of a cancer in a subject in need thereof.
- the dominant negative protein is SMRAD 51
- Anti -cancer agents may be Melphalan, Vincristine (Oncovin), Cyclophosphamide (Cytoxan), Etoposide (VP-16), Doxorubicin (Adriamycin), Liposomal doxorubicin (Doxil) and Bendamustine (Treanda).
- Others anti-cancer agents may be for example mitomycin C, cytarabine, anthracyclines, fludarabine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cyclophosphamide, ifosfamide, nitrosoureas, platinum complexes such as cisplatin, carboplatin and oxaliplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epimbicm, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin
- additional anticancer agents may be selected from, but are not limited to, one or a combination of the following class of agents: alkylating agents, plant alkaloids, DNA topoisomerase inhibitors, anti-folates, pyrimidine analogs, purine analogs, DNA antimetabolites, taxanes, podophyllotoxin, hormonal therapies, retinoids, photosensitizers or photodynamic therapies, angiogenesis inhibitors, antimitotic agents, isoprenylation inhibitors, cell cycle inhibitors, actinomycins, bleomycins, MDR inhibitors, PARP inhibitors and Ca2+ ATPase inhibitors.
- Additional anti-cancer agents may be selected from, but are not limited to, cytokines, chemokines, growth factors, growth inhibitory factors, hormones, soluble receptors, decoy receptors, monoclonal or polyclonal antibodies, mono-specific, bi-specific or multi-specific antibodies, monobodies, polybodies.
- Additional anti-cancer agent may be selected from, but are not limited to, growth or hematopoietic factors such as erythropoietin and thrombopoietin, and growth factor mimetics thereof.
- the further therapeutic active agent can be an antiemetic agent.
- Suitable antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acethylleucine monoemanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dunenhydrinate, diphenidol, dolasetron, meclizme, methallatal, metopimazine, nabilone, oxypemdyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol s, thiefhylperazine, thioproperazine and tropisetron.
- the further therapeutic active agent can be an hematopoietic colony stimulating factor.
- Suitable hematopoietic colony stimulating factors include, but are not limited to, filgrastim, sargramostim, molgramostim and epoietin alpha.
- the other therapeutic active agent can be an opioid or non opioid analgesic agent.
- opioid analgesic agents include, but are not limited to, morphine, heroin, hydromorphone, hydrocodone, oxymorphone, oxycodone, metopon, apomorphine, nomioiphine, etoipbine, buprenorphine, mepeddine, lopermide, anileddine, ethoheptazine, piminidine, betaprodine, diphenoxylate, fentanil, sufentanil, alfentanil, remifentanil, levorphanol, dextromethorphan, phenazodne, pemazocine, cyclazocine, methadone, isomethadone and propoxyphene.
- Suitable non-opioid analgesic agents include, but are not limited to, aspirin, celecoxib, rofecoxib, diclofmac, diflusinal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, indomethacin, ketorolac, meclofenamate, mefanamic acid, nabumetone, naproxen, piroxicam and sulindac.
- the further therapeutic active agent can be an anxiolytic agent.
- Suitable anxiolytic agents include, but are not limited to, buspirone, and benzodiazepines such as diazepam, lorazepam, oxazapam, chlorazepate, clonazepam, chlordiazepoxide and alprazolam.
- the further therapeutic active agent can be a immune checkpoint blockade cancer immunotherapy agent.
- the immune checkpoint blockade cancer immunotherapy agent is an agent which blocks an immunosuppressive receptor expressed by activated T lymphocytes, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1), or by NK cells, like various members of the killer cell immunoglobulin like receptor (KIR) family, or an agent which blocks the principal ligands of these receptors, such as PD-1 ligand CD274 (best known as PD-L1 or B7-H1).
- CTL4 cytotoxic T lymphocyte-associated protein 4
- PDCD1 programmed cell death 1
- NK cells like various members of the killer cell immunoglobulin like receptor (KIR) family, or an agent which blocks the principal ligands of these receptors, such as PD-1 ligand CD274 (best known as PD-L1 or B7-H1).
- the checkpoint blockade cancer immunotherapy agent is an antibody.
- the checkpoint blockade cancer immunotherapy agent is an antibody selected from the group consisting of anti-CTLA4 antibodies, anti -PD 1 antibodies, anti-PDLl antibodies, anti-PDL2 antibodies, anti-TIM-3 antibodies, anti-LAG3 antibodies, anti -IDO 1 antibodies, anti-TIGIT antibodies, anti-B7H3 antibodies, anti-B7H4 antibodies, anti- BTLA antibodies,
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention for use for treating cancer is administered in combination with an immune checkpoint blockade cancer immunotherapy agent.
- SMRAD51 protein or fragment thereof or the agent for SMRAD51 protein expression for use for treating cancer is administered in combination with an immune checkpoint blockade cancer immunotherapy agent.
- the further therapeutic active agent can be radiotherapy.
- the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention for use for treating cancer is administered in combination with radiotherapy.
- the SMRAD51 protein or fragment thereof or the agent for SMRAD51 protein expression according to the invention can be use in combination with radiotherapy.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention is administered sequentially or concomitantly with one or more therapeutic active agent.
- said additional active compounds may be contained in the same composition or administrated separately.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression according to the invention as described above are administered to the subject in a therapeutically effective amount.
- a “therapeutically effective amount” of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention as above described is meant a sufficient amount of the S the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression for treating a cancer at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; the duration of the treatment; drugs used in combination or coincidental with the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; and like factors well known in the medical arts.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
- the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention, preferably from 1 mg to about 100 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention.
- An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression according to the invention may be used in a concentration between 0.01 mM and 20 mM, particularly, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention may be used in a concentration of 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 pM.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention is administered to the subject in the form of a pharmaceutical composition.
- the invention also relates to a therapeutic composition comprising a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
- the invention also relates to a therapeutic composition comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression for use in the treatment of a cancer in a subject in need thereof.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
- pharmaceutically acceptable excipients such as a carboxylate, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, ethylene glycol, glycerol, glycerol, adiluent, encapsulating material or formulation auxiliary of any type.
- the active principle in the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
- Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
- the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- Solutions comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention can be formulated into a composition in a neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized agent of the present inventions into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- sterile powders for the preparation of sterile injectable solutions the typical methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the preparation of more, or highly concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small tumor area.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
- parenteral administration in an aqueous solution for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
- the pharmaceutical composition of the invention relates to combined preparation for simultaneous, separate or sequential use in the treatment of a cancer in a subject in need thereof.
- the present invention relates to a method for treating a cancer in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a dominant negative of RAD51.
- the invention also relates to a method for treating a cancer in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a dominant negative protein or fragment thereof and/or an agent for the dominant negative protein expression according to the invention.
- kits comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention.
- FIGURES are a diagrammatic representation of FIGURES.
- Figure 1 effect of SMRAD51 on the viability of different transformed human cells.
- the is a clonogenic assay the values correspond to the number of cell colonies after two week of culture in the presence of G418. Empty: transfection of a plasmid containing the G418 resistant gene but not SMRAD51 (control). The values are normalized to each corresponding control, i.e. for each corresponding cell line.
- CG human fibroblasts transformed by SV40. U20S: from human osteosracome.
- HeLa from human cervical cancer.
- HCT116 from human colorectal carcinoma (wild-type for Tp53).
- HCT116 p53KO from human colorectal carcinoma (KO for Tp53).
- the graph represents the ⁇ SEM of at least three independent experiments. Each situation is statistically significant (student’s t-test).
- FIG. 2 Impact of the TRP51 status on the survival upon expression of SMRAD51 and two other dominant negative forms RAD51 (RAD51 K133A or RAD51 K133R).
- the values correspond to the number of cell colonies of HCT116 cells (colon cancer), after two week of culture in the presence of G418.
- Black bars wild-type for TRP53; white bars: TRP53 KO.
- the graph represents the ⁇ SEM of at least three independent experiments.
- Figure 3 Induction of apoptosis (monitored by the Anexin V assay) at diffrent days (D) after expression of the different RAD51 dominant negative forms (noted on the right part of the figures).
- the graph represents the ⁇ SEM of at least three independent experiments. * indicate the statistical significance
- Figure 4 Functional inhibition of Rad51 induces inflammation in young growing mice. Real-time RT-PCR analysis of Ctrl and SMRad51 skin samples.
- FIG. 5 In vivo SMRad51 expression in mice with mammary tumors decreases tumor growth and tumorigenesis.
- A Quantitative analysis of tumor growth by tumor size measurements after 0, 2 and 4 weeks of Dox treatment in PyMT; Ctrl and PyMT; SMRad51.
- B Quantitative analysis of tumor prevalence in PyMT; Ctrl and PyMT; SMRad51 submitted to a Dox containing diet starting for 4 weeks.
- A The graph represents the ⁇ SEM of 5 mice from two independent litters for each group.
- Each point in the graphs represents an independent biological replicate.
- Statistical analysis (A) Two-way ANOVA followed by Sidak’s multiple comparisons test and (B) student’s t-test. *p ⁇ 0,05 and ****p ⁇ 0,0001.
- Example 1 In vitro use of SMRAD51 on different cancerous human cells lines
- pBL99 pcDNA3 plasmid with a puromycin resistance (PuroR) gene.
- PuroR puromycin resistance
- SMRad51 plasmid contains the SMRad51 transgene cloned into the pBL99 vector. 5pg/mL of puromycin was added to the cell medium one day after transfection to select for transfected cells.
- Cell medium was changed 4 and 8 days after transfection and fresh antibiotic was added to the medium. Twelve days after transfection and growth under selective pressure, cell medium was removed and cell colonies were stained with a Crystal Violet solution, made of 5 g/L of Crystal Violet (Sigma #C0775) in 20 % Ethanol, for at least 15 minutes. Cells were rinsed with PBS and clones were counted by hand.
- a Crystal Violet solution made of 5 g/L of Crystal Violet (Sigma #C0775) in 20 % Ethanol, for at least 15 minutes. Cells were rinsed with PBS and clones were counted by hand.
- Cancerous/transformed human cells lines have been transfected with a plasmid that contains a resistance gene to G418 and the SMRAD51 transgene or no transgene (control) ( Figure 1). After transfection, the G418 selection is applied so as to keep only the cells truly transfected by the plasmid and the occurrence of the clones is achieved 12 days after the transfections (clonogenic assay). The cells lines transfected with SMRAD51 showed a lower number of colonies compared to cell transfected with empty expression vector (which contains only the G418 resistant gene). This demonstrates the toxicity and anti-cancerous effect of SMRAD51, in human cells from different kinds of tumors.
- Example 2 In vitro use of others dominant negatives on different cancerous human cells lines
- Cells were harvested 2, 3 and 4 days after transfection. Immediately after harvesting, cells were incubated with Annexin-V FITC and PI using Invitrogen’s Apoptosis Kit (#V13242) and according to the manufacturer’s instructions. The percentage of FITC and PI expressing cells was scored by FACS analysis using a BD Accuri C6 Flow Cytometer.
- SMRAD51 or two other RAD51 dominant negative forms mutated on the same residue, RAD51 K133A or RAD51 K133R, were transfected (using a plasmid bearing a G418 resistant gene) into HCT116 (colon cancer) cells, either wild-type for TRP53 or KO for TRP53.
- the toxicity of the transgenes was measured by a clonogenic assay after 12-15 days of culture in the presence of G418 (see example 1). Compared to empty control plasmid (containing only the G418 resistant gene), the presence of SMRAD51 RAD51 K133A or RAD51 K133R leads to cell toxicity independently of the TRP53 status ( Figure 2).
- RAD51 Different dominant negative forms of RAD51 (SMRAD51, RAD51 K133A, RAD51 K133R, RAD51, RADI IDA, RAD51 T131P K133R) or DMC1 were transfected in U20S (osteosarcoma) cells, then apoptosis was measured at different days (D) after transfection. 4 days after transfection (D4), all dominant negative forms of RAD51 significantly induce apoptosis ( Figure 3).
- Example 3 In vivo expression of SMRAD51 leads to premature aging rather than tumor development
- mice exMmRad51 (HA-tagged Mus musculus Rad51) and SMRad51 -containing mice were generated using the following strategy.
- ExMmRad51 and SMRad51 were derived from previously developed plasmid constructs (Lambert and Lopez, 2000). Both transgenes were subcloned from a pcDNA3.1-puro plasmid containing exMmRad51 and SMRad51 to a pBI-4 plasmid containing the tet operators. The vectors were then linearized and electroporated into ES cells (129/SVEV). The clones were selected using puromycin and injected into blastocysts to enable germline transmission.
- mice containing the lox-stop-lox rtTA-EGFP transgene B6.Cg-Gt(ROSA)26SorTMl(rtTA,EGFP)Nagy/J
- mice containing the lox-stop-lox rtTA-EGFP transgene B6.Cg-Gt(ROSA)26SorTMl(rtTA,EGFP)Nagy/J
- Vasa-Cre mice FVB-Tg(Ddx4-cre)lDcas/J
- mice were kept in a mixed genetic background. In young growing mice, in vivo transgene expression was induced by intraperitoneal injections of Dox diluted in PBS (5 pg/g, Sigma #D9891) on Monday, Wednesday and/or Friday. In adult mice, in vivo transgene expression was induced by ad libitum feeding of a diet with 625 mg/kg Dox (Sigma #D9891). All mice used as controls were treated with Dox.
- GraphPad Prism software was used for statistical analysis. One- or two-way ANOVA was performed as indicated. The p-values are based on two-sided tests.
- mice were compared to Dox-exposed control littermates (rtTA-;SMRad51+ and rtTA-;exMmRad51+) that bore the transgenes but not the transcription activator rtTA and thus did not express the transgenes in the presence of Dox.
- mice We fed 3-month-old adult mice ad libitum with Dox-containing food (data not shown).
- SMRad51, but not exMmRad51 mice started to show features of premature aging, including reduced activity, hair loss, intermittent priapism and abnormal posture with protuberance of the upper back (data not shown).
- X-ray imaging by micro-computed tomography (pCT) after 4 months of Dox treatment revealed that these back changes were associated with curvature of the spine, consistent with kyphosis (data not shown).
- Prolonged expression of SMRad51, but not exMmRad51 decreased both body weight and life span (data not shown).
- SMRad51 we next investigated whether in vivo expression of SMRad51 also induces a systemic inflammatory response in young growing mice. No differences in the density of WBCs, RBCs or hemoglobin (HGB) were observed between SMRad51 -expressing and control growing mice (7 days of Dox treatment) (data not shown) However, SMRad51 expression decreased B-lymphocyte numbers and increased monocyte numbers (data not shown), in agreement with the induction of inflammation (Cain D. et al. Cell Rep (2016); Shi C. et al. J Invest Dermatol (2009)). To further analyze the systemic effects of SMRad51 expression, we performed a serum cytokine array analysis (data not shown).
- SMRad51 containing mice were generated. Littermates obtained from the crosses of SMRad51 (rtTA; SMRad51) with control (SMRad51) were used for experimental analysis.
- the breast cancer model MMTV; PyMT (FVB/N-Tg(MMTV-PyVT)634Mul/J) mice were mated with SMRad51 (rtTA; SMRad51) to generate rtTA; SMRad51; MMTV -PyMT (PyMT; SMRad51) and SMRad51; MMTV-PyMT (PyMT; Ctrl) mice. All mice were kept in a mixed genetic background. In vivo transgene expression was induced by ad libitum diet of doxycycline 625 mg/kg (Sigma #D9891) added food. All mice used as control were treated with doxycycline.
- Each PyMT; Ctrl and PyMT; SMRad51 cells were isolated from a mammary gland tumor of a MMTV-PyMT transgenic female mouse. In sterile conditions, tumor cells were cut into small pieces using a razor and, then, subjected to enzymatic digestion with 5mL of tripsin 0,25% (Therm oFisher, #25200056) for 30 min in a petri’s dish.
- Protein extraction was performed using RIPA (ThermoFisher #89900) supplemented with phosphatase (ThermoFisher #P0044 and #P5726) and protease (ThermoFisher #78438) inhibitors. After SDS-PAGE protein separation the proteins were transferred to a nitrocellulose membrane for lh 110V at 4°C. The following primary antibodies were diluted in milk 5% prior to incubation: anti-RAD51 (1:1000, Millipore, #PC130), anti-VINCULIN (1:10000, Abeam, #AB18058), anti-pH3 (S10) (1:1000, Merck Millipore, 06-570).
- HRP-conjugated secondary antibodies were from ThermoFisher (1:10000), anti-mouse IgG, cat #31430, anti-rabbit IgG, #31460).
- ECL systems PIERCE ThermoFisher #32106, were used according to the manufacturer’s instructions.
- Graphpad Prism software was used for statistical analysis t-test, one or two-way ANOVA were performed as indicated p-values are based on two-sided tests. Immunofluorescence analysis and quantification was performed using FIJI (Image J).
- Mammary cells present high levels of HR-mediated DSB repair (Kass et ak, 2016) and mutations in HR genes are associated with breast cancer or ovarian cancer (A. L. Heeke et ak, and D. Angeli, 2020). For these reasons, we took advantage of the MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) transgenic mouse, a widely used and well-characterized mammary tumor model, to investigate the contribution functional inactivation of RAD51 on tumorigenesis and tumor progression.
- MMTV-PyMT mouse mammary tumor virus-polyoma middle tumor-antigen
- MMTV- PyMT With the transgenic mice developed here rtTA; SMRad51 mice to generate rtTA; SMRad51; MMTV-PyMT (herein called PyMT; SMRad51) and control littermates (herein called PyMT; Ctrl).
- PyMT MMTV-PyMT
- Ctrl control littermates
- MMTV-PyMT mice show a sequential tumor formation, where the cervical and thoracic gland tumors are observed prior to the abdominal and inguinal ones.
- cervical and thoracic palpable tumors started to be observed in 4 months old females and abdominal and inguinal palpable tumors in 5 months old.
- SMRad51 4 month old females to a Dox diet for 4 weeks.
- SMRad51 expression decreased tumor growth as observed by tumor size measurements ( Figure 5A) and reduced the number of palpable tumors ( Figure 5B). Therefore, in vivo expression of SMRAD51 inhibits both tumor growth and initiation in the PyMT breast cancer model.
- SMRad51 mice Less advanced lesions were found in SMRad51 mice, as only 2 of 5 were invasive carcinoma grade 3 and 3 of 5 mice were invasive carcinoma grade 2 (data not shown). In agreement with an inhibition in tumor evolution, SMRad51 expressing tumors often presented non-invasive adenomas/mammary intraepithelial neoplasias (data not shown). These data show that RAD51 functional inactivation inhibits tumor progression.
- SMRad51 Chronic activation of the DNA damage response by expression of SMRad51 can create cell autonomous and non-autonomous effects that suppress tumor growth and progression.
- induction of SMRAD51 was observed after Dox treatment in PyMT; SMRad51, but not PyMT; Ctrl, cell lines (data not shown).
- expression of SMRad51 heavily impacted cell proliferation, as analyzed by population growth (data not shown). This data show that SMRAD51 induce a cell autonomous effect inhibiting cell proliferation in PyMT breast tumors derived cell lines.
- the inhibition of cell proliferation upon RAD51 functional inhibition can be caused by cell cycle arrest and/or cell death.
- SMRAD51 inhibit cell proliferation we first analyzed the cell cycle progression by BrDU incorporation in PyMT breast tumors derived cell lines. Short after SMRad51 expression started (2 days) an increase in the proportion of G2/M cells and a decrease in the S-phase cells could be observed. After 4 days of SMRad51 expression an even more pronounced increase in the G2/M cells was observed, which was associated with a decrease in G1 cells (data not shown). No differences were observed in the control cell line after Dox treatment (data not shown). These data show that the presence of SMRAD51 disturb cell cycle progression, particularly arresting cell cycle in G2/M.
- SMRAD51 inhibits tumor initiation, growth and progression in vivo, in a mouse model of breast cancer.
- RAD51 functional inactivation increases the activation of DNA damage and replication stress response in pre- neoplasic and neoplastic lesions in vivo.
- data from newly established cell lines from mouse breast tumors show that functional inactivation of RAD51 causes cell cycle arrest in G2, cell death and inhibit cell proliferation.
- expression of SMRAD51 in different human cell limes originating from different type of cancer also impair they proliferation.
- useful of SMRAD51 could be a new promising tool to treat different kinds of cancers, including breast cancers.
Abstract
The present invention relates to the treatment of cancer In this study, the inventors decided to directly address this hypothesis and investigated the effects of RAD51 functional disruption by dominants negative like the protein SMRAD51 on tumorigenesis and tumor progression using a mouse model of breast cancer. Thus, the present invention relates to dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
Description
A DOMINANT NEGATIVE PROTEIN OF RAD51 FOR TREATING CANCER
FIELD OF THE INVENTION:
The present invention relates to a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
BACKGROUND OF THE INVENTION:
In human, RAD51, a 339-amino acid protein, plays a major role in homologous recombination (HR) of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks. In this process, an ATP dependent DNA strand exchange takes place in which a single stranded DNA (ssDNA) invades base- paired strands of a homologous duplex DNA molecule. When loaded on the ssDNA, RAD51 promotes the search for homology, strand invasion and strand exchange stages of the process.
Because HR is essential for genome stability maintenance, inactivation of HR factors is directly associated with cancer susceptibility. However, in spite of its central role in HR, RAD5 1 mutations are paradoxically not commonly found in human cancer. In previous works, the inventors reported that the expression of the engineered RAD51 dominant negative protein SMRAD5 1 suppresses HR and affects the DNA replication dynamics, leading to replication stress and genome instability in unchallenged primary cells as well as in transformed cells. Importantly, the inventors characterize the molecular mechanism of HR inhibition (Inhibition of the RAD51/ssDNA activity of homology search and strand exchange) and they show that this is not associated with the stimulation of alternative mutagenic repair pathways. Expression of SMRad51 in vivo in young growing mice leads to an abrupt lethality partially caused by a systemic inflammatory response. In adult mice, SMRad51 expression leads to premature aging but not to tumorigenesis. This was unexpected because inactivation of HR partners of RAD51, such as BRCA1 or BRCA2, leads to cancer susceptibility. However, this was consistent with the paradoxical observations in genetic clinical analyses, validating thus the animal models designed by the inventors, for their relevance to human cancer. Both in adult and young growing mice proliferative tissues are preferentially affected, particularly progenitor cells that are replicating. This is consistent with the impact of RAD51 suppression on DNA replication dynamic. These tissues accumulate markers of DNA damages and apoptosis. Moreover, the tissues expresses inflammatory cytokines and immune cells (macrophages, lymphocyte B) are recruited suggesting that the innate immunity system was activated.
In addition, loss of function of the tumor suppressor TRP53, which should suppress apoptosis and reduce senescence, in fact does not increase tumorigenesis but, on the opposite, it reduced the life span of SMRad51 expressing adult mice. The inventors have shown that the expression of SMRAD51 in TRP53 devoid cells increase mitotic catastrophe. Therefore, the absence of cell cycle checkpoint resulting from TRP53 ablation precipitates SMRAD51- expressing cells, which exhibit replication stress, toward mitotic catastrophe and death.
Because of the role of HR in replication dynamic, the impact in vivo on proliferating tissues/cells and the stronger phenotype in young growing animals (that have more replicating cells) compared to adults, the inventors made the hypothesis that SMRAD51 would block the expansion of highly proliferative cells, including transformed cells, therefore not allowing tumors to form or leading to the death of replicating tumor cells.
Therefore, they hypothesis that SMRAD51, which leads to the specific death of proliferative cells, could be used to treat cancer.
SUMMARY OF THE INVENTION:
In this study, the inventors decided to directly address this hypothesis and investigated the effects of RAD51 functional disruption by dominants negative like the protein SMRAD51 on tumorigenesis and tumor progression using a mouse model of breast cancer.
Thus, the present invention relates to dominants negative of RAD51 for use in the treatment of a cancer in a subject in need thereof. Particularly, the invention is defined by its claims.
DETAILED DESCRIPTION OF THE INVENTION:
The mouse model PyMT is a model of breast tumors predisposition. Here the inventors showed that expression of SMRAD51 in this model led to both a decrease in the number of tumors and in reduced size of the tumors. RAD51 functional inactivation increases the activation of DNA damage and replication stress response in pre-neoplasic and neoplastic lesions in vivo. In addition, data show that functional inactivation of RAD51 causes cell cycle arrest in G2, cell death and inhibit cell proliferation. These data support that SMRAD51 counteract tumor initiation and progression.
A first aspect of the invention relates to a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
As used herein, the term “dominant negative of RAD51” denotes a molecule/protein/product which adversely affects endogenous RAD51 (the normal protein) and
thus which can still interact with the same elements as RAD51 and/or with RAD51 partners and/or endogenous RAD51 itself, but block its function that’s is to say its role in homologous recombination (HR) of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks.
According to the invention, a dominant negative of RAD51 can be the protein SMRAD51, a fragment of SMRAD51 or any agent for SMRAD51 protein expression, the protein RAD51 K133A, a fragment of RAD51 K133A or any agent for RAD51 K133A protein expression, the protein RAD51 K133R, a fragment of RAD51 K133R or any agent for RAD51 K133R protein expression, the protein RAD51 T131P, a fragment of RAD51 T131P or any agent for RAD51 T131P protein expression, the protein RAD51 IDA, a fragment of RAD51 IDA or any agent for RAD51 IDA protein expression, the protein DMC1, a fragment or variant of DMC1 or any agent for DMC1 protein expression.
According to the invention, the dominant negative is a RAD51 which is not the human RAD51 that is to say a RAD51 from another specie than human.
According to the invention, the dominant negative is an human, mouse or yeast chimeric protein (SMRAD51) or a mutant human, a mutant mouse or chimeric protein RAD51 K133A, RAD51 K133R, RAD51 T31P, RAD51 IDA or DMC1.
Thus, in a particular embodiment, the invention also relates to the SMRAD51 protein or fragment thereof or an agent for SMRAD51 protein expression for use in the treatment of a cancer in a subject in need thereof.
As used herein and for example, the term “an agent for SMRAD51 protein expression” denotes an agent which can instore the SMRAD51 protein expression. Thus, an agent for SMRAD5 1 protein expression can be a nucleic acid encoding for SMRAD51 or for a fragment of SMRAD51.
Thus, the term “an agent for the dominant negative proteins of the invention expression” denotes an agent which can instore the dominant negative proteins expression. Thus, an agent for the dominant negative proteins expression can be a nucleic acid encoding for the dominant negative proteins of the invention or for a fragment thereof.
Thus, in a particular embodiment, the invention relates to a dominant negative protein or fragment thereof and/or an agent for the dominant negative protein expression for use in the treatment of a cancer in a subject in need thereof.
In particular embodiments, the dominant negative protein is selected from the group consisting of an human, mouse or yeast chimeric protein (SMRAD51) or a mutant human, a
mutant mouse or chimeric protein RAD51 K133A, RAD51 K133R, RAD51 T31P, RAD51 IDA or DMC1
As used herein, the term “subject” denotes a mammal. Typically, a subject according to the invention refers to any subject (particularly an human) afflicted with or susceptible to be afflicted with a cancer.
According to the invention, the cancer may be selected in the group consisting of adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, breast cancer, Castleman disease, cervical cancer, colorectal cancer, endometrial cancer, esophagus cancer, gallbladder cancer, gastrointestinal carcinoid tumors, Hodgkin's disease, Kaposi's sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung cancer, mesothelioma, plasmacytoma, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cavity and oropharyngeal cancer, ovarian cancer, pancreatic cancer, penile cancer, pituitary cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, vaginal cancer, vulvar cancer, and uterine cancer.
As used herein, the term "treatment" or "treat" refer to both prophylactic or preventive treatment as well as curative or disease-modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse. The treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment. By "therapeutic regimen" is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy. A therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease. The general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen. An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance period" refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the
maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
The term “SMRAD51” has its general meaning in the art and refers to the RAD51 dominant negative protein. As used herein “RAD51” is a 339-amino acid protein that plays a major role in homologous recombination of DNA during double strand break repair, interstrand crosslinks repair and protection and resumption of arrested replication forks. In this process, an ATP dependent DNA strand exchange takes place in which a single-strand invades base-paired strands of homologous DNA molecules. When loaded on the ssDNA, RAD51 promotes the search for homology and strand pairing stages of the process. The protein SMRAD51 has an of amino acid sequence SEQ ID NO: 1.
In some embodiments, the SMRAD51, RAD51 K133A, RAD51 K133R, RAD51 IDA or DMC1 proteins of the invention are isolated, synthetic or recombinant proteins.
In one embodiment, the SMRAD51 protein comprises a sequence as set forth by SEQ ID NO: 1.
Amino acids sequence of the chimeric yeast/mouse SMRAD51 (SEQ ID NO: 1):
MSQVQEQHISESQLQYGNGSLMSTVPADLSQSVVDGNGNGSSEDIEATNGAM QMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAVAYAPKKELI NIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETGS ITEMF GEFRT GKT QICHTL A VT C QLPIDRGGGEGK AM YIDTEGTFRPERLL A V AERY G L SGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTD YSGR GELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNI IAHASTTRLYLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
In one embodiment, the SMRAD51 protein comprises a sequence as set forth by SEQ ID NO: 2.
Amino acids sequence of the chimeric yeast/human SMRAD51 (SEQ ID NO: 2): MSQVQEQHISESQLQYGNGSLMSTVPADLSQSVVDGNGNGSSEDIEATNGAM QMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAVAYAPKKEL
INIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETG SITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERY GLSGSDVLDNVAYARGFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSG RGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGG NIIAHASTTRL YLRKGRGETRICKI YD SPCLPEAEAMF AIN DGV GD AKD
In one embodiment, the RAD51 K133A human protein comprises a sequence as set forth by SEQ ID NO: 3.
Amino acids sequence of the human RAD51 K133A (SEQ ID NO: 3) (see J. M. Stark et al, 2002):
MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAV AY APKKELINIKGI SEAK ADKIL AE AAKL VPMGF TT ATEFHQRRSEIIQITT GSKELDKL LQGGIETGSITEMFGEFRTGATQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARAFNTDHQTQLL Y Q AS AMMVESRY ALLIVD SAT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
In one embodiment, the RAD51 K133 A mouse protein comprises a sequence as set forth by SEQ ID NO: 4.
Amino acids sequence of the mouse RAD51 K133A (SEQ ID NO: 4) (see J. M. Stark et al, 2002):
MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRT GATQICHTL AVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYD SPCLPEAEAMF AINADGV GD AKD
In one embodiment, the RAD51 K133R human protein comprises a sequence as set forth by SEQ ID NO: 5.
Amino acids sequence of the human RAD51 K133R (SEQ ID NO: 5) (see J. M. Stark et al, 2002):
MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAV AY APKKELINIKGI SEAK ADKIL AE AAKL VPMGF TT ATEFHQRRSEIIQITT GSKELDKL
LQGGIETGSITEMFGEFRTGRTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARAFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYD SPCLPEAEAMF AINADGV GD AKD
In one embodiment, the RAD51 K133R mouse protein comprises a sequence as set forth by SEQ ID NO: 6.
Amino acids sequence of the mouse RAD51 K133R (SEQ ID NO: 6) (see J. M. Stark et al, 2002):
MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AY APKKELINIKGISE AK ADKILTE AAKLVPMGFTT ATEFHQRRSEIIQITT GSKELDKL LQGGIET GSITEMF GEFRT GRT QICHTL A VTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD SAT AL YRTDYSGRGELSARQMHL ARFLRMLLRL ADEFGVAVVITNQVVAQ VDGAAMF AAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYD SPCLPEAEAMF AINADGV GD AKD
In one embodiment, the RAD51 T13 IP human protein comprises a sequence as set forth by SEQ ID NO: 7.
Amino acids sequence of the human RAD51 T131P (SEQ ID NO: 7) (see: A. T. Wang et al., 2015):
MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRPGKT QICHTL AVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD SAT AL YRTD Y S GRGEL S ARQMHL ARFLRMLLRL ADEF G V A V VITN Q V V AQ VDGAAMF A AD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
In one embodiment, the RAD51 T13 IP mouse protein comprises a sequence as set forth by SEQ ID NO: 8.
Amino acids sequence of the mouse RAD51 T131P (SEQ ID NO: 8) (see: A. T. Wang et al., 2015):
MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRPGKT QICHTL AVTCQLPIDRGGGEGKAMYIDTEGTFRPERL
L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYD SPCLPEAEAMF AINADGV GD AKD
In one embodiment, the RAD51 IDA human protein comprises a sequence as set forth by SEQ ID NO: 9.
Amino acids sequence of the human RAD51 IDA (SEQ ID NO: 9, reference number PMID: 31562309):
MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIETGSITEMFGEFATGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD SAT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNI IAHASTTRLYLAKGRGETRICAIYDSPCLPEAEAMFAINADGVGDAKD
In one embodiment, the RAD51 IDA mouse protein comprises a sequence as set forth by SEQ ID NO: 10.
Amino acids sequence of the mouse RAD51 IDA (SEQ ID NO: 10, reference number PMID: 31562309):
MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIETGSITEMFGEFATGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD SAT AL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLAKGRGETRICAIYDSPCLPEAEAMF AIN ADGVGD AKD
In one embodiment, the human DMC1 variant 1 protein comprises a sequence as set forth by SEQ ID NO: 11.
Amino acids sequence of the human DMC1 variant 1 (SEQ ID NO: 11): MKEDQVVAEEPGFQDEEESLFQDIDLLQKHGINVADIKKLKSVGICTIKGIQMT TRRALCNVKGLSEAKVDKIKEAANKLIEPGFLTAFEYSEKRKMVFHITTGSQEFDKLL GGGIESM AITEAF GEFRT GKTQL SHTLC VT AQLPGAGGYPGGKIIFIDTENTFRPDRLR DI ADRFNVDHD A VLDN VL Y AR A YT SEHQMELLD Y V A AKFHEE AGIFKLLIID SIM AL
FRVDF SGRGELAERQQKLAQMLSRLQKISEEYNVAVF VTNQMTADPGATMTF Q ADP KKPIGGHILAHASTTRISLRKGRGELRIAKIYDSPEMPENEATFAITAGGIGDAKE
In one embodiment, the human DMC1 variant 2 protein comprises a sequence as set forth by SEQ ID NO: 12.
Amino acids sequence of the human DMC1 variant 2 (SEQ ID NO: 12):
MKEDQVVAEEPGFQDEEESLFQDIDLLQKHGINVADIKKLKSVGICTIKGIQMT TRRALCNVKGLSEAKVDKIKEAANKLIEPGFLTAFEYSEKRKMVFHITTGSQEFDKLL GGGIESMAITEAFGEFRTGKTQLSHTLCGEHQMELLDYVAAKFHEEAGIFKLLIIDSIM ALFRVDF SGRGEL AERQQKL AQML SRLQKISEEYN VAVF VTN QMT ADPGATMTF Q A DPKKPIGGHIL AH AS TTRI SLRKGRGELRI AKI YD SPEMPENE ATF AIT AGGIGD AKE
In a particular embodiment, a dominant negative protein can be a protein with the amino acid sequence of RAD 51 (SEQ ID NO: 13 or 14) with at least 10 amino acids added at the N- Terminal part or C-terminal part of RAD51.
Amino acids sequence of the human RAD51 (SEQ ID NO: 13):
MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRT GKT QICHTL AVTCQLPIDRGGGEGK AMYIDTEGTFRPERL LAVAERYGLSGSDVLDNVAYARGFNTDHQTQLLYQASAMMVESRYALLIVDSATAL YRTDYSGRGELSARQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYD SPCLPEAEAMF AINADGV GD AKD
Amino acids sequence of the mouse RAD51 (SEQ ID NO: 14): MAMQMQLEASADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGYHTVEAV AYAPKKELINIKGISEAKADKILTEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKL LQGGIET GSITEMF GEFRT GKT QICHTL AVTCQLPIDRGGGEGK AMYIDTEGTFRPERL L AVAERY GLSGSD VLDNVAY ARGFNTDHQTQLL Y Q AS AMMVESRY ALLIVD S AT AL YRTD Y S GRGEL S ARQMHL ARFLRMLLRL ADEF G V A V VITN Q V V AQ VDGAAMF AAD PKKPIGGNIIAHASTTRL YLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD
In some embodiments, the dominant negative proteins of the present invention comprises or consists of an amino acid sequence having at least 70% of identity with SEQ ID NO: 1, 2, 3, 4, 5, 6 7, 8, 9, 10, 11, 12, 13 or 14.
According to the invention a first amino acid sequence having at least 70% of identity with a second amino acid sequence means that the first sequence has 70; 71; 72; 73; 74; 75; 76; 77; 78; 79; 80; 81; 82; 83; 84; 85; 86; 87; 88; 89; 90; 91; 92; 93; 94; 95; 96; 97; 98; or 99, or 100% of identity with the second amino acid sequence. Amino acid sequence identity is preferably determined using a suitable sequence alignment algorithm and default parameters, such as BLAST P (Karlin and Altschul, 1990). In particular the Ar SMRAD51 pin protein of the invention is a functional conservative variant of the SMRAD51 protein according to the invention. As used herein the term “function-conservative variant" are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the dominant negative proteins of the invention, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Accordingly, a "function-conservative variant" also includes an dominant negative proteins of the invention which has at least 70 % amino acid identity and which has the same or substantially similar properties or functions as the native or parent dominant negative proteins of the invention to which it is compared. Functional properties of the dominant negative proteins of the invention of the invention could typically be assessed in any functional assay as described in the EXAMPLE.
In another particularly embodiment, the fragment of the dominant negative proteins of the invention can be a peptide of at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 consecutive amino acids from SEQ ID NO: 1, 2, 3, 4, 5, 6 7, 8, 9, 10, 11, 12, 13 or 14.
The inventors have shown that SMRad51 expression leads to a systemic proinflammatory response in both adult and growing mice and activate innate immunity.
Thus, in some embodiments, the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to turn cold tumors into hot tumors.
In other word, the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to turn tumors who do not respond to immunotherapy into tumors who do not respond to immunotherapy.
In particular, the SMRAD51 or fragment thereof and/or an agent for the SMRAD51 expression is able to turn cold tumors into hot tumors.
As used herein, the term “cold tumor” has its general meaning in the art and refers to immune-excluded tumors and immune-desert tumors, i.e a tumor that is not likely to trigger a
strong immune response. Cold tumors usually do not respond to immunotherapy. Most cancers of the breast, ovary, prostate, pancreas, and brain (glioblastoma) are considered cold tumors.
As used herein, the term “hot tumor” has its general meaning in the art and refers to immune-inflamed tumors characterized by high T-cell infiltration, increased interferon-g (IFN- g) signaling, expression of PD-L1. Hot tumors usually respond to immunotherapy.
The inventors have shown that SMRDA51 inhibits homologous recombination (HR). They have demonstrated that SMRDA51 binds damaged DNA and represses GC (gene conversion) but does not stimulate non conservative mechanisms (SSA and A-EJ), as detailed in So A. et al. Nucleic Acids Res. 2022 Feb 8. Thus, SMRDA51 prevents genomic instability and thus mutagenesis, which is a is a hallmark of aging and cancer.
Thus, in some embodiments, the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is able to prevent excessive genomic instability and/or mutagenesis.
In particular, the SMRAD51 or fragment thereof and/or an agent for the SMRAD51 expression is able to prevent excessive genomic instability and/or mutagenesis.
A further aspect of the present invention relates to a fusion protein comprising the protein or peptide according to the invention (a dominant negative of RAD51 according to the invention) that is fused to at least one heterologous polypeptide.
The term “fusion protein” refers to the protein or peptide according to the invention that is fused directly or via a spacer to at least one heterologous polypeptide.
According to the invention, the fusion protein comprises the protein or peptide according to the invention that is fused either directly or via a spacer at its C-terminal end to the N-terminal end of the heterologous polypeptide, or at its N-terminal end to the C-terminal end of the heterologous polypeptide.
As used herein, the term “directly” means that the (first or last) amino acid at the terminal end (N or C-terminal end) of the protein or peptide is fused to the (first or last) amino acid at the terminal end (N or C-terminal end) of the heterologous polypeptide.
In other words, in this embodiment, the last amino acid of the C-terminal end of said protein or peptide is directly linked by a covalent bond to the first amino acid of the N-terminal end of said heterologous polypeptide, or the first amino acid of the N-terminal end of said protein or peptide is directly linked by a covalent bond to the last amino acid of the C-terminal end of said heterologous polypeptide.
As used herein, the term “spacer” refers to a sequence of at least one amino acid that links the protein or peptide of the invention to the heterologous polypeptide. Such a spacer may be useful to prevent steric hindrances.
In some embodiments, the heterologous polypeptide is a cell-penetrating peptide, a Transactivator of Transcription (TAT) cell penetrating sequence, a cell permeable peptide or a membranous penetrating sequence.
The term “cell-penetrating peptides” are well known in the art and refers to cell permeable sequence or membranous penetrating sequence such as penetratin, TAT mitochondrial penetrating sequence and compounds (Bechara and Sagan, 2013; Jones and Sayers, 2012; Khafagy el and Morishita, 2012; Malhi and Murthy, 2012).
The proteins, peptides or fusion proteins of the invention may be produced by any technique known per se in the art, such as, without limitation, any chemical, biological, genetic or enzymatic technique, either alone or in combination. Knowing the amino acid sequence of the desired sequence, one skilled in the art can readily produce said proteins, peptides or fusion proteins, by standard techniques for production of amino acid sequences. For instance, they can be synthesized using well-known solid phase method, preferably using a commercially available peptide synthesis apparatus (such as that made by Applied Biosystems, Foster City, California) and following the manufacturer’s instructions. Alternatively, the proteins, peptides or fusion proteins of the invention can be synthesized by recombinant DNA techniques as is now well-known in the art. For example, these fragments can be obtained as DNA expression products after incorporation of DNA sequences encoding the desired (poly) peptide into expression vectors and introduction of such vectors into suitable eukaryotic or prokaryotic hosts that will express the desired (poly) peptide, from which they can be later isolated using well- known techniques.
The proteins, peptides or fusion proteins of the invention can be used in an isolated (e.g., purified) form or contained in a vector, such as a membrane or lipid vesicle (e.g. a liposome).
In specific embodiments, it is contemplated that proteins, peptides or fusion proteins according to the invention may be modified in order to improve their therapeutic efficacy and their stability using well-known techniques. Such modification of therapeutic compounds may be used to decrease toxicity, increase circulatory time, or modify biodistribution. For example, the toxicity of potentially important therapeutic compounds can be decreased significantly by combination with a variety of drug carrier vehicles that modify biodistribution.
A strategy for improving drug stability is the utilization of water-soluble polymers. Various water-soluble polymers have been shown to modify biodistribution, improve the mode
of cellular uptake, change the permeability through physiological barriers; and modify the rate of clearance from the body. To achieve either a targeting or sustained-release effect, water- soluble polymers have been synthesized that contain drug moieties as terminal groups, as part of the backbone, or as pendent groups on the polymer chain.
For example, Pegylation is a well-established and validated approach for the modification of a range of polypeptides (Chapman, 2002). The benefits include among others: (a) markedly improved circulating half-lives in vivo due to either evasion of renal clearance as a result of the polymer increasing the apparent size of the molecule to above the glomerular filtration limit, and/or through evasion of cellular clearance mechanisms; (b) reduced antigenicity and immunogenicity of the molecule to which PEG is attached; (c) improved pharmacokinetics; (d) enhanced proteolytic resistance of the conjugated protein (Cunningham- Rundles et.ak, 1992); and (e) improved thermal and mechanical stability of the PEGylated polypeptide.
Therefore, advantageously, the proteins, peptides or fusion proteins of the invention may be covalently linked with one or more polyethylene glycol (PEG) group(s). One skilled in the art can select a suitable molecular mass for PEG, based on how the pegylated polypeptide will be used therapeutically by considering different factors including desired dosage, circulation time, resistance to proteolysis, immunogenicity, etc.
In one embodiment, the PEG of the invention terminates on one end with hydroxy or methoxy, i.e., X is H or CEP ("methoxy PEG"). In addition, such a PEG can consist of one or more PEG side-chains which are linked together. PEGs with more than one PEG chain are called branched PEGs. Branched PEGs can be prepared, for example, by the addition of polyethylene oxide to various polyols, including glycerol, pentaerythriol, and sorbitol. For example, a four-armed branched PEG can be prepared from pentaerythriol and ethylene oxide. One form of PEGs includes two PEG side-chains (PEG2) linked via the primary amino groups of a lysine (Monfardini et ak, 1995).
To effect covalent attachment of PEG groups to the polypeptide, the hydroxyl end groups of the polymer molecule must be provided in activated form, i. e. with reactive functional groups (examples of which include primary amino groups, hydrazide (HZ), thiol, succinate (SUC), succinimidyl succinate (SS), succinimidyl succinamide (SSA), succinimidyl proprionate (SPA), succinimidyl carboxymethylate (SCM),benzotriazole carbonate (BTC), N- hydroxysuccinimide (NHS), aldehyde, nitrophenyl carbonate (NPC), and tresylate (TRES)). Suitable activated polymer molecules are commercially available, e. g. from Shearwater Polymers, Inc., Huntsville, AL, USA, or from PolyMASC Pharmaceuticals pic, UK.
Alternatively, the polymer molecules can be activated by conventional methods known in the art, e. g. as disclosed in WO 90/13540. Specific examples of activated linear or branched polymer molecules for use in the present invention are described in the Shearwater Polymers, Inc. 1997 and 2000 Catalogs (Functionalized Biocompatible Polymers for Research and pharmaceuticals, Polyethylene Glycol and Derivatives, incorporated herein by reference). Specific examples of activated PEG polymers include the following linear PEGs : NHS-PEG (e g. SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM- PEG), and NOR-PEG, BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs such as PEG2-NHS.
The conjugation of the proteins, peptides or fusion proteins and the activated polymer molecules is conducted by use of any conventional method. Conventional methods are known to the skilled artisan. The skilled person will be aware that the activation method and/or conjugation chemistry to be used depends on the attachment group(s) of the polypeptides as well as the functional groups of the PEG molecule (e.g., being amine, hydroxyl, carboxyl, aldehyde, ketone, sulfhydryl, succinimidyl, maleimide, vinylsulfone or haloacetate).
In one embodiment, the proteins, peptides or fusion proteins of the invention are conjugated with PEGs at amino acid D and E (for COOH), T, Y and S (for OH), K (for MB), C (for SH if at least one cysteine is conserved) or/and Q and N (for the amide function).
In one embodiment, additional sites for PEGylation can be introduced by site-directed mutagenesis by introducing one or more lysine residues. For instance, one or more arginine residues may be mutated to a lysine residue. In another embodiment, additional PEGylation sites are chemically introduced by modifying amino acids on proteins, peptides or fusion proteins of the invention.
In one embodiment, PEGs are conjugated to the polypeptides or fusion proteins through a linker. Suitable linkers are well known to the skilled person. A preferred example is cyanuric chloride ((Abuchowski et ah, 1977); US 4,179, 337).
Conventional separation and purification techniques known in the art can be used to purify pegylated polypeptides of the invention, such as size exclusion (e.g. gel filtration) and ion exchange chromatography. Products may also be separated using SDS-PAGE.
In one embodiment, the pegylated polypeptides provided by the invention have a serum half-life in vivo at least 50%, 75%, 100%, 150% or 200% greater than that of an unmodified polypeptide.
In some embodiments, the agent for SMRAD51 protein expression of the invention is selected from the group consisting of an isolated, synthetic or recombinant nucleic acid encoding for a dominant negative of RAD51 according to the invention and particularly SMRAD5 1 protein, a nucleic acid sequence encoding for the fusion protein, a nucleic acid encoding a fragment of a dominant negative of RAD51 according to the invention and particularly SMRAD51 protein, a nucleic acid encoding a fragment of a peptide according to the invention, a cell expressing a dominant negative of RAD51 according to the invention and particularly SMRAD51 protein, and agent inducing a dominant negative of RAD51 expression according to the invention and particularly SMRAD51 gene expression and their combinations.
In one embodiment, said nucleic acid encoding for SMRAD51 proteins comprises a sequence as set forth by SEQ ID NO: 15 or 16.
Nucleic acid sequence of the chimeric yeast/mouse SMRAD51 (SEQ ID NO: 15): tgtctcaagttcaagaacaacatatatcagagtcacagcttcagtacgggaacggttcgttgatgtccactgtaccagcagac ctttcacagtcagtcgttgatggaaacggcaacggtagcagcgaagatattgaggccaccaacggcgctatgcaaatgcagcttgaag caagtgcagatacttcagtggaagaagaaagttttggtccacagcctatttcacggttagagcagtgtggcataaatgccaatgatgtga agaaattagaagaagccggttaccatacagtggaggctgttgcttatgcaccgaagaaggaactaataaatattaagggaattagtgaa gccaaagctgacaaaattctgactgaggcagcaaaattggttccaatgggtttcaccacggcaactgagtttcaccagcgccggtcaga gatcatacagataactactggctccaaagagctggacaagctgcttcaaggtggaattgagactggatctatcacagagatgtttggag aattccgaactgggaagacacagatctgtcatacgttggctgttacatgccagctccccattgaccgtggtggaggtgaagggaaggc catgtacattgacaccgagggcacctttaggccggagcggctgctagcagtagctgagagatacggtctctctggcagcgatgtccta gataatgtagcatatgcgcgagggttcaacacagaccaccagacccagctcctttaccaagcgtcagccatgatggtagaatccaggt atgcactgcttattgtagacagtgctactgccctttacagaacagactactcagggcggggagagctttcagccaggcaaatgcatttgg ccagatttctgaggatgctgcttcgacttgctgatgagtttggtgtcgcagtggtaatcaccaaccaggtagtagcccaagtagatggag cagccatgttcgctgcagatcccaaaaaacccattggagggaacatcatcgctcatgcgtcaaccaccaggctgtacctgagaaaagg aagaggggagaccagaatctgcaaaatctatgactctccctgtcttcctgaagctgaagctatgtttgccattaatgcagatggagtggg cgatgccaaagactga
Nucleic acid sequence of the chimeric yeast/human SMRAD51 (SEQ ID NO: 16): atgtctcaagttcaagaacaacatatatcagagtcacagcttcagtacgggaacggttcgttgatgtccactgtaccagcaga cctttcacagtcagtcgttgatggaaacggcaacggtagcagcgaagatattgaggccaccaacggcgcaatgcagatgcagcttga agcaaatgcagatacttcagtggaagaagaaagctttggcccacaacccatttcacggttagagcagtgtggcataaatgccaacgatg tgaagaaattggaagaagctggattccatactgtggaggctgttgcctatgcgccaaagaaggagctaataaatattaagggaattagtg aagccaaagctgataaaattctggctgaggcagctaaattagttccaatgggtttcaccactgcaactgaattccaccaaaggcggtcag agatcatacagattactactggctccaaagagcttgacaaactacttcaaggtggaattgagactggatctatcacagaaatgtttggaga attccgaactgggaagacccagatctgtcatacgctagctgtcacctgccagcttcccattgaccggggtggaggtgaaggaaaggcc
atgtacattgacactgagggtacctttaggccagaacggctgctggcagtggctgagaggtatggtctctctggcagtgatgtcctggat aatgtagcatatgctcgagcgttcaacacagaccaccagacccagctcctttatcaagcatcagccatgatggtagaatctaggtatgca ctgcttattgtagacagtgccaccgccctttacagaacagactactcgggtcgaggtgagctttcagccaggcagatgcacttggccag gtttctgcggatgcttctgcgactcgctgatgagtttggtgtagcagtggtaatcactaatcaggtggtagctcaagtggatggagcagc gatgtttgctgctgatcccaaaaaacctattggaggaaatatcatcgcccatgcatcaacaaccagattgtatctgaggaaaggaagag gggaaaccagaatctgcaaaatctacgactctccctgtcttcctgaagctgaagctatgttcgccattaatgcagatggagtgggagatg ccaaagactga
In one embodiment, said nucleic acid encoding for the human DMC1 variant 1 protein comprises a sequence as set forth by SEQ ID NO: 17.
Nucleic acid sequence of the human DMC1 variant 1 (SEQ ID NO: 17): atgaaggaggatcaagttgtggcggaagaaccaggattccaagatgaagaggaatctttgtttcaagatattgacctgttaca gaaacatggaattaacgtggctgacattaagaaactgaaatcagtaggaatctgtaccatcaaaggtatacagatgacaacaagaaga gctctatgcaatgtcaaaggactctcagaagccaaagtagacaagattaaagaggcagcgaacaaactaattgaaccaggattcttgac tgcatttgagtatagtgaaaagaggaaaatggttttccatatcaccaccgggagccaggaatttgataagttactaggaggtggaattga aagtatggcaattacagaagcttttggagaatttcgtactggaaaaacccagctttctcataccctctgtgtgacagctcaacttccaggag ctggtggctacccaggaggaaagattatcttcattgatacagaaaatactttccgtccagatcgccttagggacattgctgatcgctttaat gtagaccatgatgcagtactggacaacgtactttatgcacgtgcatatactagtgaacatcagatggagctacttgattatgtagcagcaa agttccatgaagaagctggcatcttcaagctattgattatcgattcaataatggcactttttcgagtggatttcagtggccgtggggagttgg ccgaacggcagcaaaaattggcccagatgttgtcacgactccaaaaaatctcagaagaatataacgtggctgtttttgtgaccaatcaaa tgactgccgatccaggagcaactatgacctttcaggcagatcccaaaaaacccattgggggacacattctggctcatgcttcaacaaca agaataagcttgcgaaagggaagaggagagctcagaattgccaagatttatgacagtcctgagatgcctgaaaatgaagccaccttcg caataactgctggaggaattggggatgccaaggagtag
In one embodiment, said nucleic acid encoding for the human DMC1 variant 2 protein comprises a sequence as set forth by SEQ ID NO: 18.
Nucleic acid sequence of the human DMC1 variant 2 (SEQ ID NO: 18): atgaaggaggatcaagttgtggcggaagaaccaggattccaagatgaagaggaatctttgtttcaagatattgacctgttaca gaaacatggaattaacgtggctgacattaagaaactgaaatcagtaggaatctgtaccatcaaaggtatacagatgacaacaagaaga gctctatgcaatgtcaaaggactctcagaagccaaagtagacaagattaaagaggcagcgaacaaactaattgaaccaggattcttgac tgcatttgagtatagtgaaaagaggaaaatggttttccatatcaccaccgggagccaggaatttgataagttactaggaggtggaattga aagtatggcaattacagaagcttttggagaatttcgtactggaaaaacccagctttctcataccctctgtggtgaacatcagatggagcta cttgattatgtagcagcaaagttccatgaagaagctggcatcttcaagctattgattatcgattcaataatggcactttttcgagtggatttca gtggccgtggggagttggccgaacggcagcaaaaattggcccagatgttgtcacgactccaaaaaatctcagaagaatataacgtgg ctgtttttgtgaccaatcaaatgactgccgatccaggagcaactatgacctttcaggcagatcccaaaaaacccattgggggacacattct
ggctcatgcttcaacaacaagaataagcttgcgaaagggaagaggagagctcagaattgccaagatttatgacagtcctgagatgcct gaaaatgaagccaccttcgcaataactgctggaggaattggggatgccaaggagtag
Nucleic acid sequence of the human RAD51 (SEQ ID NO: 19): atggcaatgcagatgcagcttgaagcaaatgcagatacttcagtggaagaagaaagctttggcccacaacccatttcacggt tagagcagtgtggcataaatgccaacgatgtgaagaaattggaagaagctggattccatactgtggaggctgttgcctatgcgccaaag aaggagctaataaatattaagggaattagtgaagccaaagctgataaaattctggctgaggcagctaaattagttccaatgggtttcacca ctgcaactgaattccaccaaaggcggtcagagatcatacagattactactggctccaaagagcttgacaaactacttcaaggtggaattg agactggatctatcacagaaatgtttggagaattccgaactgggaagacccagatctgtcatacgctagctgtcacctgccagcttccca ttgaccggggtggaggtgaaggaaaggccatgtacattgacactgagggtacctttaggccagaacggctgctggcagtggctgaga ggtatggtctctctggcagtgatgtcctggataatgtagcatatgctcgagcgttcaacacagaccaccagacccagctcctttatcaagc atcagccatgatggtagaatctaggtatgcactgcttattgtagacagtgccaccgccctttacagaacagactactcgggtcgaggtga gctttcagccaggcagatgcacttggccaggtttctgcggatgcttctgcgactcgctgatgagtttggtgtagcagtggtaatcactaat caggtggtagctcaagtggatggagcagcgatgtttgctgctgatcccaaaaaacctattggaggaaatatcatcgcccatgcatcaac aaccagattgtatctgaggaaaggaagaggggaaaccagaatctgcaaaatctacgactctccctgtcttcctgaagctgaagctatgtt cgccattaatgcagatggagtgggagatgccaaagactga
Nucleic acid sequence of the mouse RAD51 (SEQ ID NO: 20): atggctatgcaaatgcagcttgaagcaagtgcagatacttcagtggaagaagaaagttttggtccacagcctatttcacggtta gagcagtgtggcataaatgccaatgatgtgaagaaattagaagaagccggttaccatacagtggaggctgttgcttatgcaccgaaga aggaactaataaatattaagggaattagtgaagccaaagctgacaaaattctgactgaggcagcaaaattggttccaatgggtttcacca cggcaactgagtttcaccagcgccggtcagagatcatacagataactactggctccaaagagctggacaagctgcttcaaggtggaat tgagactggatctatcacagagatgtttggagaattccgaactgggaagacacagatctgtcatacgttggctgttacatgccagctccc cattgaccgtggtggaggtgaagggaaggccatgtacattgacaccgagggcacctttaggccggagcggctgctagcagtagctga gagatacggtctctctggcagcgatgtcctagataatgtagcatatgcgcgagggttcaacacagaccaccagacccagctcctttacc aagcgtcagccatgatggtagaatccaggtatgcactgcttattgtagacagtgctactgccctttacagaacagactactcagggcgg ggagagctttcagccaggcaaatgcatttggccagatttctgaggatgctgcttcgacttgctgatgagtttggtgtcgcagtggtaatca ccaaccaggtagtagcccaagtagatggagcagccatgttcgctgcagatcccaaaaaacccattggagggaacatcatcgctcatgc gtcaaccaccaggctgtacctgagaaaaggaagaggggagaccagaatctgcaaaatctatgactctccctgtcttcctgaagctgaa gctatgtttgccattaatgcagatggagtgggcgatgccaaagactga
In some embodiments, the nucleic acid encoding for the dominant negative protein of the invention for example comprises or consists of a sequence at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 % identical to sequence SEQ ID NO: 15, 16, 17, 18, 19 or 20.
As used herein, a sequence "encoding" an expression product, such as a DNA, RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that DNA, RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme. A coding sequence for a protein may include a start codon (usually ATG) and a stop codon.
These nucleic acid sequences can be obtained by conventional methods well known to those skilled in the art. Typically, said nucleic acid is a DNA or RNA molecule, which may be included in a suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage, viral vector, a liposome, or a nanoparticle like the clay mineral sepiolite or nano-diamonds.
So, a further object of the present invention relates to a vector and an expression cassette in which a nucleic acid molecule encoding for a proteins, peptides or fusion proteins of the invention is associated with suitable elements for controlling transcription (in particular promoter, enhancer and, optionally, terminator) and, optionally translation, and also the recombinant vectors into which a nucleic acid molecule in accordance with the invention is inserted. These recombinant vectors may, for example, be cloning vectors, or expression vectors.
As used herein, the terms "vector", "cloning vector" and "expression vector" mean the vehicle by which a DNA or RNA sequence (e.g. a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g. transcription and translation) of the introduced sequence.
Any expression vector for animal cell can be used. Examples of suitable vectors include pAGE107 (Miyaji et ah, 1990), pAGE103 (Mizukami and Itoh, 1987), pHSG274 (Brady et ah, 1984), pKCR (O'Hare et ah, 1981), pSGl beta d2-4 (Miyaji et ah, 1990) and the like.
Other examples of plasmids include replicating plasmids comprising an origin of replication, or integrative plasmids, such as for instance pUC, pcDNA, pBR, and the like.
Other examples of viral vectors include adenoviral, lentiviral, retroviral, herpes virus and AAV vectors. Such recombinant viruses may be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of virus packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc. Detailed protocols for producing such replication-defective recombinant viruses may be found for instance in WO 95/14785, WO 96/22378, US 5,882,877, US 6,013,516, US 4,861,719, US 5,278,056 and WO 94/19478.
Examples of promoters and enhancers used in the expression vector for animal cell include early promoter and enhancer of SV40 (Mizukami and Itoh, 1987), LTR promoter and
enhancer of Moloney mouse leukemia virus (Kuwana et al., 1987), promoter (Mason et al., 1985) and enhancer (Gillies et al., 1983) of immunoglobulin H chain and the like.
A further aspect of the invention relates to a host cell comprising a nucleic acid molecule encoding for a protein, peptide or a fusion protein according to the invention or a vector according to the invention. In particular, a subject of the present invention is a prokaryotic or eukaryotic host cell genetically transfected or transformed with at least one nucleic acid molecule or vector according to the invention.
The term "transformation" (for prokaryotic host cell) or “transfection” (for eukaryotic host cell) means the introduction of a "foreign" (i.e. extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence. A prokaryotic host cell that receives and expresses introduced DNA or RNA has been "transformed". A eukaryotic host cell that receives and expresses introduced DNA or RNA has been "transfected".
In a particular embodiment, for expressing and producing proteins, peptides or fusion proteins of the invention, prokaryotic cells, in particular E. coli cells, will be chosen. Actually, according to the invention, it is not mandatory to produce the proteins, peptides or fusion proteins of the invention in a eukaryotic context that will favour post-translational modifications (e.g. glycosylation). Furthermore, prokaryotic cells have the advantages to produce protein in large amounts. If a eukaryotic context is needed, yeasts (e.g. saccharomyces strains) may be particularly suitable since they allow production of large amounts of proteins. Otherwise, typical eukaryotic cell lines such as CHO, BHK-21, COS-7, C127, PER.C6, YB2/0, HEK293, mononuclear macrophage/monocyte-lineage hematopoietic precursors, Haematopoietic stem cells, Mononuclear precursor cells, osteoblast or inactive osteoclast could be used, for their ability to process to the right post-translational modifications of the fusion protein of the invention. In a particular embodiment, insect cells can be used for expressing and producing proteins, peptides or fusion proteins of the invention.
The construction of expression vectors in accordance with the invention, and the transformation of the host cells can be carried out using conventional molecular biology techniques. The protein, peptide or the fusion protein of the invention, can, for example, be obtained by culturing genetically transformed cells in accordance with the invention and recovering the proteins, peptides or fusion proteins expressed by said cell, from the culture. They may then, if necessary, be purified by conventional procedures, known in themselves to those skilled in the art, for example by fractional precipitation, in particular ammonium sulfate
precipitation, electrophoresis, gel filtration, affinity chromatography, etc. In particular, conventional methods for preparing and purifying recombinant proteins may be used for producing the proteins in accordance with the invention.
A further aspect of the invention relates to a method for producing a protein, peptide or a fusion protein of the invention comprising the step consisting of: (i) culturing a transformed host cell according to the invention under conditions suitable to allow expression of said protein, peptide or fusion protein; and (ii) recovering the expressed protein, peptide or fusion protein.
In some embodiments, the agent for SMRAD51 protein expression of the invention is an agent inducing SMRAD51 gene and peptide expression selected from the group consisting of, but not limited to, Human Cytomegalovirus (HCMV), VHL/E HCMV strain, and TB40/E HCMV strain.
In some embodiments, the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention is administered in combination with one or more anti-cancer.
Thus, In a further aspect, the present invention relates to a dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention in combination with one or more anti-cancer agent for use in the treatment of a cancer in a subject in need thereof.
In some embodiment, the dominant negative protein is SMRAD 51 Anti -cancer agents may be Melphalan, Vincristine (Oncovin), Cyclophosphamide (Cytoxan), Etoposide (VP-16), Doxorubicin (Adriamycin), Liposomal doxorubicin (Doxil) and Bendamustine (Treanda).
Others anti-cancer agents may be for example mitomycin C, cytarabine, anthracyclines, fludarabine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cyclophosphamide, ifosfamide, nitrosoureas, platinum complexes such as cisplatin, carboplatin and oxaliplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, L-asparaginase, doxorubicin, epimbicm, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, nitrosoureas such as carmustme and lomustine, vinca alkaloids such as vinblastine, vincristine and vinorelbine, imatimb mesylate, hexamethyhnel amine, topotecan, kinase inhibitors, phosphatase inhibitors, ATPase inhibitors, tyrphostins, protease inhibitors, inhibitors herbimycm A, genistein, erbstatin, and lavendustin A. In one embodiment, additional anticancer agents may be selected from, but are not limited to, one or a combination of the
following class of agents: alkylating agents, plant alkaloids, DNA topoisomerase inhibitors, anti-folates, pyrimidine analogs, purine analogs, DNA antimetabolites, taxanes, podophyllotoxin, hormonal therapies, retinoids, photosensitizers or photodynamic therapies, angiogenesis inhibitors, antimitotic agents, isoprenylation inhibitors, cell cycle inhibitors, actinomycins, bleomycins, MDR inhibitors, PARP inhibitors and Ca2+ ATPase inhibitors.
Additional anti-cancer agents may be selected from, but are not limited to, cytokines, chemokines, growth factors, growth inhibitory factors, hormones, soluble receptors, decoy receptors, monoclonal or polyclonal antibodies, mono-specific, bi-specific or multi-specific antibodies, monobodies, polybodies.
Additional anti-cancer agent may be selected from, but are not limited to, growth or hematopoietic factors such as erythropoietin and thrombopoietin, and growth factor mimetics thereof.
In the present methods for treating cancer the further therapeutic active agent can be an antiemetic agent. Suitable antiemetic agents include, but are not limited to, metoclopromide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acethylleucine monoemanolamine, alizapride, azasetron, benzquinamide, bietanautine, bromopride, buclizine, clebopride, cyclizine, dunenhydrinate, diphenidol, dolasetron, meclizme, methallatal, metopimazine, nabilone, oxypemdyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinol s, thiefhylperazine, thioproperazine and tropisetron. In a preferred embodiment, the antiemetic agent is granisetron or ondansetron.
In another embodiment, the further therapeutic active agent can be an hematopoietic colony stimulating factor. Suitable hematopoietic colony stimulating factors include, but are not limited to, filgrastim, sargramostim, molgramostim and epoietin alpha.
In still another embodiment, the other therapeutic active agent can be an opioid or non opioid analgesic agent. Suitable opioid analgesic agents include, but are not limited to, morphine, heroin, hydromorphone, hydrocodone, oxymorphone, oxycodone, metopon, apomorphine, nomioiphine, etoipbine, buprenorphine, mepeddine, lopermide, anileddine, ethoheptazine, piminidine, betaprodine, diphenoxylate, fentanil, sufentanil, alfentanil, remifentanil, levorphanol, dextromethorphan, phenazodne, pemazocine, cyclazocine, methadone, isomethadone and propoxyphene. Suitable non-opioid analgesic agents include, but are not limited to, aspirin, celecoxib, rofecoxib, diclofmac, diflusinal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, indomethacin, ketorolac, meclofenamate, mefanamic acid, nabumetone, naproxen, piroxicam and sulindac.
In yet another embodiment, the further therapeutic active agent can be an anxiolytic agent. Suitable anxiolytic agents include, but are not limited to, buspirone, and benzodiazepines such as diazepam, lorazepam, oxazapam, chlorazepate, clonazepam, chlordiazepoxide and alprazolam.
In yet another embodiment, the further therapeutic active agent can be a immune checkpoint blockade cancer immunotherapy agent.
Typically, the immune checkpoint blockade cancer immunotherapy agent is an agent which blocks an immunosuppressive receptor expressed by activated T lymphocytes, such as cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1), or by NK cells, like various members of the killer cell immunoglobulin like receptor (KIR) family, or an agent which blocks the principal ligands of these receptors, such as PD-1 ligand CD274 (best known as PD-L1 or B7-H1).
Typically, the checkpoint blockade cancer immunotherapy agent is an antibody.
In some embodiments, the checkpoint blockade cancer immunotherapy agent is an antibody selected from the group consisting of anti-CTLA4 antibodies, anti -PD 1 antibodies, anti-PDLl antibodies, anti-PDL2 antibodies, anti-TIM-3 antibodies, anti-LAG3 antibodies, anti -IDO 1 antibodies, anti-TIGIT antibodies, anti-B7H3 antibodies, anti-B7H4 antibodies, anti- BTLA antibodies,
In particular embodiment the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention for use for treating cancer is administered in combination with an immune checkpoint blockade cancer immunotherapy agent.
In particular embodiment the SMRAD51 protein or fragment thereof or the agent for SMRAD51 protein expression for use for treating cancer is administered in combination with an immune checkpoint blockade cancer immunotherapy agent.
In yet another embodiment, the further therapeutic active agent can be radiotherapy.
Thus, in another embodiment the dominant negative protein of the invention or fragment thereof and/or an agent for the dominant negative proteins expression of the invention for use for treating cancer is administered in combination with radiotherapy.
In another embodiment the SMRAD51 protein or fragment thereof or the agent for SMRAD51 protein expression according to the invention can be use in combination with radiotherapy.
In some embodiments, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention is administered sequentially or concomitantly with one or more therapeutic active agent.
In one embodiment, said additional active compounds may be contained in the same composition or administrated separately.
Typically the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression according to the invention as described above are administered to the subject in a therapeutically effective amount.
By a "therapeutically effective amount" of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention as above described is meant a sufficient amount of the S the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression for treating a cancer at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; the duration of the treatment; drugs used in combination or coincidental with the specific the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. Typically, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention for the symptomatic adjustment of the dosage to the subject to be treated. A
medicament typically contains from about 0.01 mg to about 500 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention, preferably from 1 mg to about 100 mg of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
In a particular embodiment, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression according to the invention may be used in a concentration between 0.01 mM and 20 mM, particularly, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention may be used in a concentration of 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 pM.
According to the invention, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention is administered to the subject in the form of a pharmaceutical composition. Thus, the invention also relates to a therapeutic composition comprising a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
The invention also relates to a therapeutic composition comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression for use in the treatment of a cancer in a subject in need thereof.
Typically, the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions. "Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings. Suitable unit administration forms comprise oral-route forms such as tablets, gel
capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
Typically, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of
surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized agent of the present inventions into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the typical methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the present invention plus any additional desired ingredient from a previously sterile-filtered solution thereof. The preparation of more, or highly concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small tumor area. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
In another embodiment, the pharmaceutical composition of the invention relates to combined preparation for simultaneous, separate or sequential use in the treatment of a cancer in a subject in need thereof.
In a further aspect, the present invention relates to a method for treating a cancer in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a dominant negative of RAD51.
The invention also relates to a method for treating a cancer in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a dominant negative protein or fragment thereof and/or an agent for the dominant negative protein expression according to the invention.
The invention also provides kits comprising the dominant negative protein or fragment thereof and/or the agent for the dominant negative protein expression of the invention.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1: effect of SMRAD51 on the viability of different transformed human cells.
The is a clonogenic assay: the values correspond to the number of cell colonies after two week of culture in the presence of G418. Empty: transfection of a plasmid containing the G418 resistant gene but not SMRAD51 (control). The values are normalized to each corresponding control, i.e. for each corresponding cell line. CG: human fibroblasts transformed by SV40. U20S: from human osteosracome. HeLa: from human cervical cancer. HCT116 : from human colorectal carcinoma (wild-type for Tp53). HCT116 p53KO: from human colorectal carcinoma (KO for Tp53). The graph represents the ±SEM of at least three independent experiments. Each situation is statistically significant (student’s t-test).
Figure 2: Impact of the TRP51 status on the survival upon expression of SMRAD51 and two other dominant negative forms RAD51 (RAD51 K133A or RAD51 K133R). The values correspond to the number of cell colonies of HCT116 cells (colon cancer), after two week of culture in the presence of G418. Black bars: wild-type for TRP53; white bars: TRP53 KO. The graph represents the ±SEM of at least three independent experiments.
Figure 3: Induction of apoptosis (monitored by the Anexin V assay) at diffrent days (D) after expression of the different RAD51 dominant negative forms (noted on the right part of the figures). The graph represents the ±SEM of at least three independent experiments. * indicate the statistical significance
Figure 4 : Functional inhibition of Rad51 induces inflammation in young growing mice. Real-time RT-PCR analysis of Ctrl and SMRad51 skin samples.
Figure 5: In vivo SMRad51 expression in mice with mammary tumors decreases tumor growth and tumorigenesis. (A) Quantitative analysis of tumor growth by tumor size measurements after 0, 2 and 4 weeks of Dox treatment in PyMT; Ctrl and PyMT; SMRad51. (B) Quantitative analysis of tumor prevalence in PyMT; Ctrl and PyMT; SMRad51 submitted to a Dox containing diet starting for 4 weeks. (A) The graph represents the ±SEM of 5 mice from two independent litters for each group. (B) Each point in the graphs represents an independent biological replicate. Statistical analysis: (A) Two-way ANOVA followed by Sidak’s multiple comparisons test and (B) student’s t-test. *p<0,05 and ****p<0,0001.
EXAMPLES:
Example 1: In vitro use of SMRAD51 on different cancerous human cells lines
Material & Methods
Plasmid transfection and antibiotics selection
Cells were transfected with plasmids 3 days after seeding, with Jet-PEi (Polyplus #101), according to the manufacturer’s instructions. Cell medium was changed 3h30 after transfection. The control “empty plasmid” (pBL99) is a modified pcDNA3 plasmid with a puromycin resistance (PuroR) gene. The SMRad51 plasmid contains the SMRad51 transgene cloned into the pBL99 vector. 5pg/mL of puromycin was added to the cell medium one day after transfection to select for transfected cells.
Clonogenicitv assay (crystal violet staining)
Cell medium was changed 4 and 8 days after transfection and fresh antibiotic was added to the medium. Twelve days after transfection and growth under selective pressure, cell medium was removed and cell colonies were stained with a Crystal Violet solution, made of 5 g/L of Crystal Violet (Sigma #C0775) in 20 % Ethanol, for at least 15 minutes. Cells were rinsed with PBS and clones were counted by hand.
Results
Cancerous/transformed human cells lines have been transfected with a plasmid that contains a resistance gene to G418 and the SMRAD51 transgene or no transgene (control) (Figure 1). After transfection, the G418 selection is applied so as to keep only the cells truly transfected by the plasmid and the occurrence of the clones is achieved 12 days after the transfections (clonogenic assay). The cells lines transfected with SMRAD51 showed a lower number of colonies compared to cell transfected with empty expression vector (which contains
only the G418 resistant gene). This demonstrates the toxicity and anti-cancerous effect of SMRAD51, in human cells from different kinds of tumors.
Cell cycle analysis show that cells expressing SMRAD51 arrested at the transition G2/M and massively die from apoptosis (data not shown).
Example 2: In vitro use of others dominant negatives on different cancerous human cells lines
Material & MethodsClonogenic assay. Same as above.
Apoptosis assay.
Cells were harvested 2, 3 and 4 days after transfection. Immediately after harvesting, cells were incubated with Annexin-V FITC and PI using Invitrogen’s Apoptosis Kit (#V13242) and according to the manufacturer’s instructions. The percentage of FITC and PI expressing cells was scored by FACS analysis using a BD Accuri C6 Flow Cytometer.
Results
SMRAD51 or two other RAD51 dominant negative forms mutated on the same residue, RAD51 K133A or RAD51 K133R, were transfected (using a plasmid bearing a G418 resistant gene) into HCT116 (colon cancer) cells, either wild-type for TRP53 or KO for TRP53. The toxicity of the transgenes was measured by a clonogenic assay after 12-15 days of culture in the presence of G418 (see example 1). Compared to empty control plasmid (containing only the G418 resistant gene), the presence of SMRAD51 RAD51 K133A or RAD51 K133R leads to cell toxicity independently of the TRP53 status (Figure 2).
Different dominant negative forms of RAD51 (SMRAD51, RAD51 K133A, RAD51 K133R, RAD51, RADI IDA, RAD51 T131P K133R) or DMC1 were transfected in U20S (osteosarcoma) cells, then apoptosis was measured at different days (D) after transfection. 4 days after transfection (D4), all dominant negative forms of RAD51 significantly induce apoptosis (Figure 3).
Example 3: In vivo expression of SMRAD51 leads to premature aging rather than tumor development
Material & Methods
Mice exMmRad51 (HA-tagged Mus musculus Rad51) and SMRad51 -containing mice were generated using the following strategy. ExMmRad51 and SMRad51 were derived from previously developed plasmid constructs (Lambert and Lopez, 2000). Both transgenes were
subcloned from a pcDNA3.1-puro plasmid containing exMmRad51 and SMRad51 to a pBI-4 plasmid containing the tet operators. The vectors were then linearized and electroporated into ES cells (129/SVEV). The clones were selected using puromycin and injected into blastocysts to enable germline transmission. For generation of the rtTA mouse line, mice containing the lox-stop-lox rtTA-EGFP transgene (B6.Cg-Gt(ROSA)26SorTMl(rtTA,EGFP)Nagy/J) were mated with Vasa-Cre mice (FVB-Tg(Ddx4-cre)lDcas/J) to obtain mice that constitutively expressed rtTA (these mice were therefore called rtTA mice). Littermates obtained from crosses of SMRad51 (rtTA;SMRad51) mice with control (SMRad51) mice or exMmRad51 (rtTA;ExMmRad51) mice with control (exMmRad51) mice were used for experimental analysis.
All mice were kept in a mixed genetic background. In young growing mice, in vivo transgene expression was induced by intraperitoneal injections of Dox diluted in PBS (5 pg/g, Sigma #D9891) on Monday, Wednesday and/or Friday. In adult mice, in vivo transgene expression was induced by ad libitum feeding of a diet with 625 mg/kg Dox (Sigma #D9891). All mice used as controls were treated with Dox.
The experimental procedures with animals were performed in accordance with French government regulations (Services Veterinaires de la Sante et de la Production Animate, Ministere de G Agriculture).
Histology
Whole tissues or biopsies were fixed in 4% PFA immediately after dissection. The fixed tissues were then dehydrated and embedded in paraffin using a Tissue-Tek tissue machine (Sakura). The paraffin blocks were sectioned (5 pm) and placed on slides. Before staining, the sections were dewaxed and rehydrated. Pathological analyses were performed on hematoxylin (Path #10047105)-, eosin (Path #10047001)- and alcoholic saffron (Path #10047028)-stained sections of at least three different mice. Colorimetric images were captured using an Olympus BX51 microscope.
Cytokine array
For protein array analysis, approximately 150 pL of blood serum containing protease inhibitors (Thermo Fisher #78438) was used. The serum was stored at -80°C until analysis. Samples from two mice of each genotype (Ctrl or SMRad51) that had been fed a Dox- containing diet for 3 months were used. A Proteome Profiler Mouse XL Cytokine Array Kit (R&D Systems #ARY028) was used following the manufacturer’s instructions. In Table S3 (adult mice) and Table S4 (young growing mice), we present the results of densitometry analysis and the comparisons.
Statistical analysis
GraphPad Prism software was used for statistical analysis. One- or two-way ANOVA was performed as indicated. The p-values are based on two-sided tests.
Results
In vivo expression of SMRAD51 leads to premature aging but not to carcinogenesis.
To analyze the in vivo consequences of specific inhibition of RAD51-HR activity, we induced the expression of SMRad51 and exMmRad51 (exogenous wild-type RAD51 from Mus musculus; serves as control) in rtTA+;SMRad51+ and rtTA+;exMmRad51+ mice, respectively. These mice were compared to Dox-exposed control littermates (rtTA-;SMRad51+ and rtTA-;exMmRad51+) that bore the transgenes but not the transcription activator rtTA and thus did not express the transgenes in the presence of Dox.
We fed 3-month-old adult mice ad libitum with Dox-containing food (data not shown). After approximately 6 weeks of Dox exposure, SMRad51, but not exMmRad51, mice started to show features of premature aging, including reduced activity, hair loss, intermittent priapism and abnormal posture with protuberance of the upper back (data not shown). X-ray imaging by micro-computed tomography (pCT) after 4 months of Dox treatment revealed that these back changes were associated with curvature of the spine, consistent with kyphosis (data not shown). Prolonged expression of SMRad51, but not exMmRad51, decreased both body weight and life span (data not shown). Collectively, these phenotypes support the induction of premature aging in SMRad51 -expressing mice but not in exMmRad51 -expressing mice.
To evaluate tissue morphological modifications caused by SMRad51 expression, we performed anatomical and histopathological analyses. After 6 months of Dox treatment, we observed testis size reductions (data not shown) and splenomegaly, as shown by increased spleen sizes (data not shown). Splenomegaly is a feature of systemic inflammation and aging in mice (Pettan-Brewer and M. Treuting, 2011). We then performed histopathological analyses of different tissues from mice fed a Dox-supplemented diet for 6 months (data not shown). These analyses revealed edematous alveolitis in the lungs of SMRad51 -expressing mice (data not shown), consistent with induction of inflammation. Moreover, SMRad51 expression decreased capillary bulb density and led to hyperplasia in the epidermis (data not shown). Subcutaneous skin fat layer thickness was reduced in SMRad51 -expressing mice compared to control mice (data not shown). Similar phenotypes are observed in mice with skin-specific CRE-LOX-mediated inactivation of Brcal (Sotiropoulou et ah, 2013). Given that BRCAl and RAD51 share roles in HR, this finding suggests that the phenotypes observed here actually resulted from HR inactivation in vivo. Notably, reductions in subcutaneous fat have been
observed in aged and prematurely aged mice (Munoz-Lorente et al., 2019). The other tissues that we analyzed did not present major histological modifications (data not shown). Importantly, although HR defects generated genetic instability (data not shown), tumors were not detected in any of our samples; only one mouse had a precancerous lesion in the skin (not tumoral) (data not shown). Altogether, these data show that SMRad51 expression leads to premature aging but not to increased tumorigenesis.
Since we observed morphological modifications associated with inflammation in several organs, we evaluated whether SMRad51 expression leads to a systemic inflammatory response. We measured the levels of cytokines in the serum of SMRad51 and control mice after three months of Dox exposure. Using cytokine arrays, we showed that among the 111 proteins analyzed, 29 were upregulated in SMRad51 mice, most of which were proinflammatory factors (data not shown). These data show that functional disruption of RAD51 leads to a systemic inflammatory response in adult mice.
Disruption of RAD51 HR activity induces inflammation in growing mice
Histopathological analysis of the skin revealed the presence of inflammatory infiltrates after 12 days of SMRad51 expression in growing mice (data not shown). Immunolocalization analysis revealed an increase in T-lymphocyte infiltration (data not shown) and monocyte/macrophage aggregates (as indicated by F4/80 staining) in skin samples (data not shown). Real-time RT-PCR showed that SMRAD51 stimulated the expression of proinflammatory cytokines in the skin (Fig. 4). Thus, SMRad51 expression leads to a tissue inflammatory response in vivo. These data are consistent with the induction of systemic inflammation observed in adult mice (data not shown). We next investigated whether in vivo expression of SMRad51 also induces a systemic inflammatory response in young growing mice. No differences in the density of WBCs, RBCs or hemoglobin (HGB) were observed between SMRad51 -expressing and control growing mice (7 days of Dox treatment) (data not shown) However, SMRad51 expression decreased B-lymphocyte numbers and increased monocyte numbers (data not shown), in agreement with the induction of inflammation (Cain D. et al. Cell Rep (2018); Shi C. et al. J Invest Dermatol (2009)). To further analyze the systemic effects of SMRad51 expression, we performed a serum cytokine array analysis (data not shown). Proinflammatory factors that were upregulated in the serum of SMRad51 adult mice, namely, Lipocalin-2/NGAL, CCL17/TARC, E-selectin/CD62A and CCL22/MDC, were also among the most upregulated factors in the serum of young mice (data not shown). These data show that SMRad51 expression leads to a systemic proinflammatory response in both adult and growing mice.
Example 4: In vivo expression of SMRAD51 inhibits mammary tumor initiation and progression in mice
Material & Methods
Mice
SMRad51 containing mice were generated. Littermates obtained from the crosses of SMRad51 (rtTA; SMRad51) with control (SMRad51) were used for experimental analysis. The breast cancer model MMTV; PyMT (FVB/N-Tg(MMTV-PyVT)634Mul/J) mice were mated with SMRad51 (rtTA; SMRad51) to generate rtTA; SMRad51; MMTV -PyMT (PyMT; SMRad51) and SMRad51; MMTV-PyMT (PyMT; Ctrl) mice. All mice were kept in a mixed genetic background. In vivo transgene expression was induced by ad libitum diet of doxycycline 625 mg/kg (Sigma #D9891) added food. All mice used as control were treated with doxycycline.
For tumor growth analysis, the diameter of palpable tumors were determined by measuring the anteroposterior length of the tumors and the formula for the volume (V) of a sphere V = 4/3 pt3 was used to determined its volume. All mice that reached the limit points indicated by the French Government regulations (Services Veterinaires de la Sante et de la Production Animate, Ministere de l'Agriculture) were sacrificed. All experimental procedures with animals were performed in accordance with French Government regulations (Services Veterinaires de la Sante et de la Production Animate, Ministere de l'Agriculture).
Histology
Whole tumors were fixed in PFA4% immediately being collected. For MMTV-PyMT histological analysis and stainings, the 4 biggest tumors of each mouse were dehydrated and embedded in paraffin using a tissue-tek tissue machine (Sakura). Paraffin blocks were sectioned (5 pm) and placed on slides. Before staining; sections were dewaxed and rehydrated. Tumor histolopathological analysis was performed in hematoxylin-eosin-safran stained histological sections and followed previously determined standards (Cardiff et ak, 2000).
MMTV-PyMT cell lines generation
Each PyMT; Ctrl and PyMT; SMRad51 cells were isolated from a mammary gland tumor of a MMTV-PyMT transgenic female mouse. In sterile conditions, tumor cells were cut into small pieces using a razor and, then, subjected to enzymatic digestion with 5mL of tripsin 0,25% (Therm oFisher, #25200056) for 30 min in a petri’s dish. Next, 25 mL of DMEM (Gibco #41965-039) supplemented with 10% FBS tetracycline-free (Takara #631107) and penicillin- streptomycin (Gibco #15140122) (herein called PyMT media) was added and the cells were plated into T75 cell culture flasks. Medium was changed regularly and the tumor cells were
selected by several passages of differential trypsinization until. The cell lines were considered established and used for experiments after passage 20 (3-4 months in culture). Transgene induction was performed using 2mM of Dox (Sigma #D9891). Cell death was analyzed using the LIVE/DEAD™ Viability/Cytotoxicity Kit (Thermo Fisher #L3224).
Cell cycle analysis by BrDU incorporation
For cell cycle analysis by BrDU incorporation, we incubated PyMT cell lines with 10 mM of BrDU. By the end of the treatment, the cells were trypsinized, collected, fixed in 100% ethanol and stored at -20°C. The fixed cells were permeabilized with pepsin (cone.), HC1 (2N) solution for 20 minuts at 37°C and then with HC1 (2N) for 20 minuts at 37°C. Cells were next washed 3 times with phosphate buffer saline (PBS) and after induebated with FITC conjugated BrDU antibody (BD556028) diluted 1:50 in BU buffer (0,5% FBS, 0,5% tween 20, 20mM hepes in PBS) for 30 minutes at 37°C. Finally, the cells nuclei were stained with a solution containing propidium iodide (PI - Sigma #P4864) for 30 minutes at 37°C.
Western blot
Protein extraction was performed using RIPA (ThermoFisher #89900) supplemented with phosphatase (ThermoFisher #P0044 and #P5726) and protease (ThermoFisher #78438) inhibitors. After SDS-PAGE protein separation the proteins were transferred to a nitrocellulose membrane for lh 110V at 4°C. The following primary antibodies were diluted in milk 5% prior to incubation: anti-RAD51 (1:1000, Millipore, #PC130), anti-VINCULIN (1:10000, Abeam, #AB18058), anti-pH3 (S10) (1:1000, Merck Millipore, 06-570). HRP-conjugated secondary antibodies were from ThermoFisher (1:10000), anti-mouse IgG, cat #31430, anti-rabbit IgG, #31460). ECL systems PIERCE (ThermoFisher #32106) were used according to the manufacturer’s instructions.
Statistical analysis
Graphpad Prism software was used for statistical analysis t-test, one or two-way ANOVA were performed as indicated p-values are based on two-sided tests. Immunofluorescence analysis and quantification was performed using FIJI (Image J).
Results
Mammary cells present high levels of HR-mediated DSB repair (Kass et ak, 2016) and mutations in HR genes are associated with breast cancer or ovarian cancer (A. L. Heeke et ak, and D. Angeli, 2020). For these reasons, we took advantage of the MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) transgenic mouse, a widely used and well-characterized mammary tumor model, to investigate the contribution functional inactivation of RAD51 on tumorigenesis and tumor progression. To do so, we crossed MMTV-
PyMT with the transgenic mice developed here rtTA; SMRad51 mice to generate rtTA; SMRad51; MMTV-PyMT (herein called PyMT; SMRad51) and control littermates (herein called PyMT; Ctrl). During the process of oncogene-derived tumorigenesis in MMTV-PyMT, mammary progenitors are under constant proliferative stress and hyperplasia lesions are observed early in life (Fluck and Schaffhausen, 2009). With time, MMTV-PyMT show full tumor penetrance: 100% of the females develop tumors (Fluck and Schaffhausen, 2009). In addition, MMTV-PyMT mice show a sequential tumor formation, where the cervical and thoracic gland tumors are observed prior to the abdominal and inguinal ones. In our genetic background, cervical and thoracic palpable tumors started to be observed in 4 months old females and abdominal and inguinal palpable tumors in 5 months old. We took advantage of these characteristics to evaluate both tumor initiation and tumor growth and submitted PyMT; Ctrl and PyMT; SMRad51 4 month old females to a Dox diet for 4 weeks. SMRad51 expression decreased tumor growth as observed by tumor size measurements (Figure 5A) and reduced the number of palpable tumors (Figure 5B). Therefore, in vivo expression of SMRAD51 inhibits both tumor growth and initiation in the PyMT breast cancer model.
Next, we evaluated whether tumor growth inhibition by SMRad51 expression would be also associated with changes in tumor progression. During PyMT mammary tumor progresion, local hyperplasic lesions are formed early (Lin et ak, 2003). With time these hyperplasias give rise to pre-malignant adenomas/mammary intraepithelial neoplasias (MIN) that are still confined by a basement membrane (Lin et ak, 2003). MIN’s can then evolve to malignant early carcinomas when presenting greater cytological atypia and stromal invasion, and after to invasive carcinomas when the tumors are formed by solid sheets of epithelial cells with without acinar structures (Lin et ak, 2003). These carcinomas are further defined as high grade when presenting pleomorphism of the nuclei, an increase in mitotic figures and multiple epithelial layers (Lin et ak, 2003). PyMT mammary lesions can also be characterized as grade 2 and 3, where grade 2 tumors present greater similarities to the normal breast tissue than grade 3 tumors. Based on these characteristics, we performed histopathological analysis on PyMT; Ctrl and PyMT; SMRad51 tumors to infer about their evolution. Hyperplasias and carcinomas were observed in both PyMT; Ctrl and PyMT; SMRad51 tumors and high level of SMRAD51 protein was observed in both (data not shown). All tumors from control mice (n=5) were invasive carcinoma grade 3 (data not shown). Less advanced lesions were found in SMRad51 mice, as only 2 of 5 were invasive carcinoma grade 3 and 3 of 5 mice were invasive carcinoma grade 2 (data not shown). In agreement with an inhibition in tumor evolution, SMRad51 expressing
tumors often presented non-invasive adenomas/mammary intraepithelial neoplasias (data not shown). These data show that RAD51 functional inactivation inhibits tumor progression.
Next, we investigated whether the presence of SMRAD51 in PyMT carcinomas and hyperplasia lesions would be associated with increased DNA damage response. Immunohistochemistry for the DNA damage response activation marker gH2AC revealed an increase the presence of damaged cells in hyperplasias and carcinomas after SMRad51 expression (data not shown). Furthermore, pCHKl (S317) immunohistochemistry revealed an increase in the proportion of cells with activated replicative stress response in SMRad51- expressing hyperplasias and cancomas (data not shown). Our results show that SMRAD51 leads to DNA damage and replication stress response activation both in pre-tumorigenic lesions (hyperplasia) and carcinomas.
Chronic activation of the DNA damage response by expression of SMRad51 can create cell autonomous and non-autonomous effects that suppress tumor growth and progression. In an attempt to separate autonomous and non-autonomous events, we collect tumors from 5 months old mice that had never been treated with Dox containing food and generate cell lines from our mouse models PyMT; Ctrl and PyMT; SMRad51. As expected, induction of SMRAD51 was observed after Dox treatment in PyMT; SMRad51, but not PyMT; Ctrl, cell lines (data not shown). In addition, expression of SMRad51 heavily impacted cell proliferation, as analyzed by population growth (data not shown). This data show that SMRAD51 induce a cell autonomous effect inhibiting cell proliferation in PyMT breast tumors derived cell lines.
The inhibition of cell proliferation upon RAD51 functional inhibition can be caused by cell cycle arrest and/or cell death. To address how SMRAD51 inhibit cell proliferation, we first analyzed the cell cycle progression by BrDU incorporation in PyMT breast tumors derived cell lines. Short after SMRad51 expression started (2 days) an increase in the proportion of G2/M cells and a decrease in the S-phase cells could be observed. After 4 days of SMRad51 expression an even more pronounced increase in the G2/M cells was observed, which was associated with a decrease in G1 cells (data not shown). No differences were observed in the control cell line after Dox treatment (data not shown). These data show that the presence of SMRAD51 disturb cell cycle progression, particularly arresting cell cycle in G2/M. To investigate cell cycle arrest would occur in G2 and/or after entry on mitosis, we evaluated the levels of pH3 (S10) a marker of CDK1 activity hallmark of mitotic cells. SMRad51 expression decreased the levels of pH3 (S10) (data not shown), showing that PyMT cells are arrested in G2. Finally, we evaluated whether these changes in cell cycle progression would be associated with modifications in cell death. An increase in cell death was observed in SMRad51 expressing
cells after 2 and 4 days (data not shown). Altogether, these results show that functional inactivation of RAD51 has a cell autonomous effect in PyMT breast tumors derived cell lines, leading to a cell cycle arrest and cell death that inhibits cell proliferation. It is likely that these events contribute, at least in part, to the inhibition of tumor initiation and progression observed in vivo in mammary tumors from PyMT expressing SMRad51. However, we cannot exclude the contribution of non-autonomous effects caused by SMRad51 expression. In particular, our data in primary cells show that SMRad51 expression can change the microenvironment by activating an inflammatory response. Since the recruitment and activation of immune cells can inhibit tumor growth/progression, it is possible that non-aunotomous events also participate in tumor growth/progression inhibition by RAD51 inactivation. Further investigations are needed to elucidate the contributions of these non-autonomous mechanisms.
Conclusion:
Here the inventors showed that expression of SMRAD51 inhibits tumor initiation, growth and progression in vivo, in a mouse model of breast cancer. RAD51 functional inactivation increases the activation of DNA damage and replication stress response in pre- neoplasic and neoplastic lesions in vivo. In addition, data from newly established cell lines from mouse breast tumors show that functional inactivation of RAD51 causes cell cycle arrest in G2, cell death and inhibit cell proliferation. Moreover, expression of SMRAD51 in different human cell limes originating from different type of cancer also impair they proliferation. Thus, useful of SMRAD51 could be a new promising tool to treat different kinds of cancers, including breast cancers.
REFERENCES:
Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are hereby incorporated by reference into the present disclosure.
Cardiff, R.D.; Anver, M.R.; Gusterson, B.A.; Hennighausen, L.; Jensen, R.A.; Merino, M.J.; Rehm, S.; Russo, J.; Tavassoli, F.A.; Wakefield, L.M.; et al. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19, 968-988.
Fluck, M.M.; Schaffhausen, B.S. Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen. Microbiol. Mol. Biol. Rev. 2009, 73, 542-563.
Kass, E.M.; Lim, P.X.; Helgadottir, H.R.; Moynahan, M.E.; Jasin, M. Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat. Commun. 2016, 7.
Lin, E.Y.; Jones, J.G.; Li, P.; Zhu, L.; Whitney, K.D.; Muller, W.J.; Pollard, J.W. Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases. Am. J. Pathol. 2003, 163, 2113-2126.
A. L. Heeke et al., Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis. Oncol., 1-13 (2018).
D. Angeli, S. Salvi, G. Tedaldi, Genetic predisposition to breast and ovarian cancers: How many and which genes to test? Int. J. Mol. Sci. 21 (2020), doi: 10.3390/ijms21031128.
J. M. Stark et al., ATP hydrolysis by mammalian RAD51 has a key role during homology- directed DNA repair. J Biol Chem. 277, 20185-20194. (2002).
A. T. Wang et al., A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. Mol. Cell. 59, 478-490 (2015).
So A, Dardillac E, Muhammad A, Chailleux C, Sesma-Sanz L, Ragu S, Le Cam E, Canitrot Y, Masson JY, Dupaigne P, Lopez BS, Guirouilh-Barbat J. RAD51 protects against nonconservative DNA double-strand break repair through a nonenzymatic function. Nucleic Acids Res. 2022 Feb 8.
Claims
1. A dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
2. The dominant negative of RAD51 for use according to claim 1 wherein the dominant negative of RAD51 is selected from the group consisting of the protein SMRAD51, a fragment of SMRAD51 or any agent for SMRAD51 protein expression, the protein RAD51 K133A, a fragment of RAD51 K133A or any agent for RAD51 K133A protein expression, the protein RAD51 K133R, a fragment of RAD51 K133R or any agent for RAD51 K133R protein expression, the protein RAD51 T131P, a fragment of RAD51 T131P or any agent for RAD51 T131P protein expression, the protein RAD51 IDA, a fragment of RAD51 II3A or any agent for RAD51 IDA protein expression, the protein DMC1, a fragment or variant of DMC1 or any agent for DMC1 protein expression.
3. The dominant negative of RAD51 for use according to claim 1 wherein the dominant negative of RAD51 is a human, mouse or yeast chimeric protein (SMRAD51) or a mutant human, a mutant mouse or chimeric protein RAD51 K133A, RAD51 K133R, RAD51 IDA or DMC1.
4. The dominant negative of RAD51 for use according to claims 2 or 3 wherein the dominant negative of RAD51 comprises a sequence as set forth by SEQ ID NO: 1 to 14.
5. The dominant negative of RAD51 for use according to any one of claim 1 to 4, wherein the dominant negative of RAD51 is administered in combination with one or more anti cancer agent.
6. The dominant negative of RAD51 for use according to claim 5, wherein the anti-cancer agent is a immune checkpoint blockade cancer immunotherapy agent.
7. A therapeutic composition comprising a dominant negative of RAD51 for use in the treatment of a cancer in a subject in need thereof.
8. A method for treating a cancer in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a dominant negative of RAD51.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21305363.0 | 2021-03-24 | ||
EP21305363 | 2021-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022200469A1 true WO2022200469A1 (en) | 2022-09-29 |
Family
ID=75497871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/057695 WO2022200469A1 (en) | 2021-03-24 | 2022-03-23 | A dominant negative protein of rad51 for treating cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022200469A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
WO1995014785A1 (en) | 1993-11-23 | 1995-06-01 | Rhone-Poulenc Rorer S.A. | Composition for the in vivo production of therapeutic products |
WO1996022378A1 (en) | 1995-01-20 | 1996-07-25 | Rhone-Poulenc Rorer S.A. | Cells for the production of recombinant adenoviruses |
US5882877A (en) | 1992-12-03 | 1999-03-16 | Genzyme Corporation | Adenoviral vectors for gene therapy containing deletions in the adenoviral genome |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
-
2022
- 2022-03-23 WO PCT/EP2022/057695 patent/WO2022200469A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
WO1990013540A1 (en) | 1989-04-19 | 1990-11-15 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5882877A (en) | 1992-12-03 | 1999-03-16 | Genzyme Corporation | Adenoviral vectors for gene therapy containing deletions in the adenoviral genome |
WO1994019478A1 (en) | 1993-02-22 | 1994-09-01 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
WO1995014785A1 (en) | 1993-11-23 | 1995-06-01 | Rhone-Poulenc Rorer S.A. | Composition for the in vivo production of therapeutic products |
WO1996022378A1 (en) | 1995-01-20 | 1996-07-25 | Rhone-Poulenc Rorer S.A. | Cells for the production of recombinant adenoviruses |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
Non-Patent Citations (16)
Title |
---|
A. L. HEEKE ET AL.: "Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types", JCO PRECIS. ONCOL., 2018, pages 1 - 13 |
A. T. WANG ET AL.: "A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination", MOL. CELL., vol. 59, 2015, pages 478 - 490, XP029255847, DOI: 10.1016/j.molcel.2015.07.009 |
BERTRAND PASCALE ET AL: "Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells", vol. 22, no. 48, 1 October 2003 (2003-10-01), London, pages 7587 - 7592, XP055838220, ISSN: 0950-9232, Retrieved from the Internet <URL:https://www.nature.com/articles/1206998.pdf> DOI: 10.1038/sj.onc.1206998 * |
CAIN D. ET AL., CELL REP, 2018 |
CARDIFF, R.D.ANVER, M.R.GUSTERSON, B.A.HENNIGHAUSEN, L.JENSEN, R.A.MERINO, M.J.REHM, S.RUSSO, J.TAVASSOLI, F.A.WAKEFIELD, L.M. ET : "The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting", ONCOGENE, vol. 19, 2000, pages 968 - 988, XP037735015, DOI: 10.1038/sj.onc.1203277 |
D. ANGELI, S. SALVI, G. TEDALDI: "Genetic predisposition to breast and ovarian cancers:How many and which genes to test?", INT. J. MOL. SCI., vol. 21, 2020 |
DE MATOS RODRIGUES GABRIEL EDUARDO: "Suppression of Homologous Recombination by RAD51 Functional Inactivation In Vivo in Mice", 17 December 2020 (2020-12-17), pages 1 - 2, XP055838087, Retrieved from the Internet <URL:http://www.theses.fr/2020UPASL073> [retrieved on 20210906] * |
FLUCK, M.M.: "Schaffhausen, B.S. Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen", MICROBIOL. MOL. BIOL. REV., vol. 73, 2009, pages 542 - 563 |
J. M. STARK ET AL.: "ATP hydrolysis by mammalian RAD51 has a key role during homology- directed DNA repair", J BIOL CHEM., vol. 277, 2002, pages 20185 - 20194 |
KASS, E.M.LIM, P.X.HELGADOTTIR, H.R.MOYNAHAN, M.E.JASIN, M.: "Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation", NAT. COMMUN., 2016, pages 7 |
LAMBERT S.: "Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms", THE EMBO JOURNAL / EUROPEAN MOLECULAR BIOLOGY ORGANIZATION, vol. 19, no. 12, 15 June 2000 (2000-06-15), Oxford, pages 3090 - 3099, XP055838144, ISSN: 0261-4189, DOI: 10.1093/emboj/19.12.3090 * |
LIN, E.Y.JONES, J.G.LI, P.ZHU, L.WHITNEY, K.D.MULLER, W.J.POLLARD, J.W.: "Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases", AM. J. PATHOL., vol. 163, 2003, pages 2113 - 2126 |
SHI C. ET AL., J INVEST DERMATOL, 2009 |
SILVA MICHELLE C ET AL: "Defects in recombination activity caused by somatic and germline mutations in the multimerization/BRCA2 binding region of human RAD51 protein", DNA REPAIR, vol. 60, 1 December 2017 (2017-12-01), pages 64 - 76, XP085267228, ISSN: 1568-7864, DOI: 10.1016/J.DNAREP.2017.10.008 * |
SO ADARDILLAC EMUHAMMAD ACHAILLEUX CSESMA-SANZ LRAGU SLE CAM ECANITROT YMASSON JYDUPAIGNE P: "RAD51 protects against nonconservative DNA double-strand break repair through a nonenzymatic function", NUCLEIC ACIDS RES., 8 February 2022 (2022-02-08) |
THOMAS MÉLISSA ET AL: "Jeunes & Chercheurs - Livret des communications soumises", 19 October 2020 (2020-10-19), pages FP1-2, 1-114, XP055838183, Retrieved from the Internet <URL:http://www3.ligue-cancer.net/docs/01_LIVRET_COMMUNICATIONS_SOUMISES_J_C.pdf> [retrieved on 20210906] * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022023099A (en) | Rna guided eradication of herpes simplex type i and other related herpesviruses | |
AU2003216288B2 (en) | Modulation of immune response by non-peptide binding stress response polypeptides | |
JP5650639B2 (en) | Treatment of tumor diseases | |
US20220401474A1 (en) | Hdac6-activated macrophages, compositions, and uses thereof | |
EP3347098B1 (en) | Targeting mda-5 activation for cancer immunotherapy | |
JP5590882B2 (en) | Cysteine-rich acidic secreted protein (SPARC) as a chemosensitizer | |
JP2020500947A (en) | Anticancer composition containing recombinant adenovirus expressing extracellular matrix degrading factor | |
JP2023022242A (en) | Methods and compositions for treating cancer | |
KR20220112241A (en) | Novel oncolytic virus platform to treat cancer using myxoma virus | |
CA2323604A1 (en) | Interferon alpha plasmids and delivery systems, and methods of making and using the same | |
US11052131B2 (en) | Methods and pharmaceutical compositions for the treatment of kidney cancer | |
Goklany et al. | Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers | |
KR20130043242A (en) | Sparc angiogenic domain and methods of use | |
US20230079955A1 (en) | Anti-muc1 compositions and methods of use | |
WO2022200469A1 (en) | A dominant negative protein of rad51 for treating cancer | |
AU2017205538B2 (en) | A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor | |
WO2001079495A1 (en) | Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer | |
WO2018213412A1 (en) | Recombinant oncolytic virus | |
TW200418876A (en) | Methods of modulating inflammation by administration of interleukin-19 and inhibitors of il-19 binding | |
WO2006026451A2 (en) | Targeted expression of apoptosis-inducing genes for disease treatment | |
Eslahi et al. | Fusogenic activity of vesicular stomatitis virus glycoprotein plasmid in tumors as an enhancer of IL-12 gene therapy | |
JP2024511119A (en) | Modified peptidomimetics and methods of use | |
WO2022020544A1 (en) | Method of treating an inflammatory condition | |
Zhang et al. | Hyaluronate-based Self-stabilized Nanoparticles for Reverting Immunosuppression and Immunochemotherapy in Osteosarcoma Treatment | |
KR20230026994A (en) | Immunostimulants in combination with angiogenesis inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22712953 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22712953 Country of ref document: EP Kind code of ref document: A1 |